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Abstract 
 
“TARGETING DRUGS TO THE LIVER: COMBINING PHARMACOKINETIC 
STUDIES AND MODELING TO OPTIMIZE TARGETING TO HEPATOCYTES 
VIA THE ASIALOGLYCOPROTEIN RECEPTOR” 
The asialoglycoprotein receptor (ASGPR) has drawn particular attention to enhance 
drug delivery to hepatocytes, notably because this membrane endocytic receptor is expressed 
almost exclusively and with high abundance on hepatocytes making this receptor a target of 
choice for hepatic delivery. In this thesis we take advantage of a newly developed anti-ASGPR 
antibody (ASGPR Ab) and mathematical modeling to infer the uptake properties of the receptor 
in vivo in mice, crucial information to optimize drug delivery to hepatocyte. This quantitative 
knowledge can then be leveraged to inform the protocol of administration of any molecular 
entity targeting the ASGPR. With an optimal dosing regimen, receptor saturation can be 
avoided to obtain a maximal delivery into hepatocytes while minimizing the likelihood for 
systemic adverse effects. 
To estimate the ASGPR mediated uptake parameters, focusing on its expression, 
turnover and internalization rates, we performed a mouse pharmacokinetic (PK) study with the 
ASGPR Ab. The ASGPR expression level was found to be about 1.8 million molecules per 
hepatocyte, which confirms the high abundancy of receptors expressed at the hepatocytes cell 
surface. The half-life of the degradation of the receptor was estimated to be about 15 hours and 
the formed ligand-receptor complex is internalized with a half-life of about 5 days. This slow 
internalization is an advantage for drug targeting as it allows to capture the free drug from the 
plasma by binding and then delivers the drug slowly into the hepatocytes even if the targeting 
drug as a fast non-ASGPR related PK in the plasma. The kinetics of the ASGPR shows that 
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saturation of the shuttle at therapeutic concentrations is possible; however, modeling and 
simulation allows the dosing protocol to be optimized.  
Then, to confirm both the specific liver uptake of the ASGPR Ab and the quantitative 
description of the ASGPR mediated uptake we performed a biodistribution study. To measure 
the uptake of the ASGPR Ab in the liver and the distribution in other tissues, the antibody was 
radiolabeled and tissue radioactivity was quantified. A large distribution of the ASGPR Ab was 
detected in liver and minor distribution was noted in other tissues, confirming the rapid and 
extensive binding of the ASGPR Ab in the liver. In order to differentiate the specific uptake of 
the ASGPR Ab from the general liver clearance of antibodies, a radiolabeled non-targeting 
antibody (IL17 Ab) was used as a control. In comparison to the ASGPR Ab, the IL17 Ab 
distributes much less in liver confirming the specific distribution of the ASGPR Ab into the 
liver.  From the biodistribution data it was possible to conclude that all the target mediated 
uptake of the ASGPR Ab happens solely in the liver and therefore confirm the quantitative 
description of the ASGPR mediated uptake. 
We suggest the following use of the ASGPR-mediated disposition model. First, it is 
applicable to any ASGPR targeting drugs by changing the PK properties which are non-
ASGPR related, e.g. volume of distribution, non-ASGPR related clearance… etc. Second, the 
ASGPR mediated drug disposition model supports the selection of an optimal dosing regimen 
by maximizing liver uptake while minimizing non targeted organs distribution. Extrapolation 
of the mouse model to human is the final goal in order to predict optimal dosing regimen of 
ASGPR targeting drugs in patients. In human, some parameters are already known such as the 
receptor expression but other processes of the receptor mediated endocytosis must however be 
investigated such as the synthesis and degradation rate. Once defined in human, the model will 
be applicable and used for two purposes 1) estimate the receptor number in patients as 
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suggested in the manuscript of the second paper 2) investigate the impact of decreased receptor 
number in the patients on the dosing regimen.  
Introduction  
 
The targeted delivery of novel therapeutics has been an attractive research area as it 
allows the drug to concentrate in specific tissues and cell types and minimize non-target related 
toxicity [1, 2]. Targeted drugs interact specifically with intended targeted cells or pathogens 
via receptors expressed at the cell surface allowing them to penetrate and concentrate in the 
cells to reach their intracellular pharmacological targets. This is of particular importance when 
molecular entities cannot enter cells on their own, such as RNAi or gene editing technologies 
mediated by CRISPR [3], or accumulate in non-targeted tissues or cells, such as nucleic acid 
therapeutics [4]. Among this emerging class of molecules, antisense oligonucleotides (ASOs) 
have elicited a great deal of interest because those molecules can be designed to target any 
mRNA. ASOs distribute extensively in liver but mostly in non-parenchymal cells and much 
less in hepatocytes. However, often to treat the most common hepatic diseases the drug must 
be delivered specifically to the hepatocytes, e.g. as for the treatment of the hepatitis B. 
For targeting the liver, the asialoglycoprotein receptor (ASGPR) has drawn particular 
attention, especially because this receptor is expressed almost exclusively and with high 
abundance [5] on hepatocytes. This transmembrane C-type lectin is an endocytic receptor that 
internalizes its ligand through receptor mediated endocytosis (RME). It recognizes a wide 
variety of ligands that contain either terminal galactose (Gal) or N-acetylgalactosamine 
(GalNAc) residues [6]. ASGPR is primarily cited for desialylated serum glycoproteins removal 
[7], however its native function has not been completely clarified. This hepatic receptor is also 
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thought to be involved in the clearance of lipoproteins [8], the hepatic fibronectin [9], apoptotic 
cells [10], immunoglobulin A [11] or involved in cell-cell interactions [12]. 
Delivery through RME is dependent on numerous factors such as e.g. the receptor 
density at the cell surface, the internalization or the recycling of the receptor or the release of 
the targeted drug from the endosome once inside the cell. The ASGPR targeting offers the 
unique opportunity to concentrate targeted molecules into hepatocytes. However, there is a risk 
to lose this advantage when saturating the ASGPR endocytic pathway at high doses of targeted 
drugs as schematically represented in Figure 1. In this thesis we take advantage of a newly 
developed anti-ASGPR antibody (ASGPR Ab) and mathematical modeling to infer the uptake 
properties of the receptor in vivo in mice. The quantitative knowledge on ASGPR expression 
level and kinetics of uptake can then be used to optimize drug delivery to hepatocyte trough 
ASGPR targeting and support the development of any therapies that use the ASGPR as a shuttle 
into hepatocytes. 
The first part of this thesis is devoted to a literature review focusing on the clinical 
relevance of ASGPR targeting. Principles and challenges of receptor mediated delivery are 
then discussed. We detail the ASGPR biology, i.e. its structure, localization and level of 
expression and physiologic function. Recognized ligands and targeting strategies that have 
been exploited are summarized. We then discuss pharmacokinetic and pharmacodynamics 
modeling approaches, such as target mediated drug disposition, and its use in case of receptor 
mediated delivery. Finally, ASGPR targeting strategies and its optimization are discussed in 
the context of drug delivery to the hepatocytes. 
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Figure 1 Escalators allegory. In this train station, four escalators and stairs are available. A. 
The escalators are not saturated, almost no one used the stairs. B. The escalators are reaching 
saturation; some people start using the stairs. C. Escalators are completely saturated and most 
people used the stairs. This situation mimics the saturation of the receptor. When completely 
saturated, the drug is not binding anymore and distribute in non-targeted tissues. As for the 
escalators, the receptor recycles back to the cell membrane to bind ligand again. In this allegory, 
two major processes are not illustrated, the synthesis and the degradation of the receptor which 
maintain the receptor expression to a baseline level. 
Not saturated 
Reaching saturation 
Beyond saturation 
A 
B 
C 
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The results of two in-vivo studies are then presented: 
 We first present the result of a pharmacokinetic study using a novel ASGPR-targeted 
antibody in vivo in mice. Combining pharmacokinetic data (intravenous and 
subcutaneous dosing) with an in-silico target-mediated drug disposition (TMDD) 
model, we estimate the expression level, turnover and internalization rates of ASGPR.  
The developed model is then used to optimize dosing protocol in term of delivery 
efficiency, i.e., maximizing internalization through receptor targeting, and therefore 
reducing the off-target distribution and unspecific clearance. The results of this study 
were published in the journal “mAbs” in 2017 [13]. 
 In a second study we design and perform a biodistribution study in mice where we 
confirm the inferred liver uptake from the previous PK study. To measure the antibody 
in tissues, the ASGPR Ab was radiolabeled with 111Indium-DOTA complex (111In) 
and Iodine-125 (125I). By integrating acquired knowledge from the first paper, we 
discuss how to optimize ASGPR targeting delivery. We demonstrate that non-specific 
clearance, i.e. non-target related, or molecular properties influence the liver uptake. 
Two optimization criteria were proposed 1) the quantity of the drug delivered in the 
liver (targeting intensity) and 2) the percentage of the drug delivered to the liver 
(delivery efficiency). A manuscript attached to this thesis is under preparation for 
publication. 
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Literature review 
 
I. Clinical relevance in ASGPR based targeting 
ASGPR targeting has been investigated i) to concentrate targeted drugs inside hepatocytes ii) 
as a diagnostic tool to estimate the remnant hepatic function before hepatectomy. The first part 
of this chapter is devoted to hepatic diseases where the root cause starts with the hepatocytes 
with a special focus on diseases with a high prevalence where ASGPR targeting would benefit 
a large number of patients. 
1. Hepatic diseases: where do we stand? 
Liver diseases are a major world public health problem especially due to chronic liver 
diseases affecting more than 844 million people worldwide [14]. Among liver diseases 
affecting the hepatocytes, different etiologies can be found such as cancers, genetic disorders 
and metabolic or infectious diseases. Table 1 summarizes hepatic diseases (which cause is 
affecting solely the hepatocytes) and indicates whether a treatment is available. 
a. Viral diseases 
Five viruses (A,B,C,D and E) are responsible of most cases of acute hepatitis with 400 
million people globally affected causing 1.34 million deaths every year (statistics from 2015 
[15]). More than 240 million people are affected by hepatitis B alone and despite vaccination, 
with a large burden of hepatitis B infection in all sub-Saharan African regions and East Asia 
[16]. A combination of sofosbuvir, velpatasvir and voxilaprevir have been recently investigated 
in patient with hepatitis C and showed high cure rates, i.e. > 90% virologic response. No 
curative treatment is currently available for the other viral hepatitis but treatments can suppress 
viral replication which unfortunately implies a lifelong therapy. 
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b. Malaria 
Malaria is another infectious liver disease with 212 million people affected worldwide 
(statistics from 2016 [17]). The treatment of this disease has improved with the use of 
artemisinin-based combination therapy which is effective and well tolerated. However, 
resistance to the treatment has emerged especially in South-East Asia.  
c. Metabolic diseases 
In addition to infectious diseases, metabolic diseases contribute to the global burden of 
hepatic diseases [18]. For example, 25 percent of the world population is now thought to be 
affected by nonalcoholic fatty liver disease (NAFLD). This liver disease has become the most 
prominent cause of chronic liver disease worldwide. The actual cause of accumulation of fat in 
liver cells remains unknown but the disease is often associated with overweight or obesity, 
dyslipidemia and diabetes mellitus [19]. Numerous genetic disorders are also responsible for 
hepatic diseases. Among them, the lysosomal storage diseases include no less than 50 rare 
inherited metabolic disorders such as Wilson’s disease, Ornithine transcarbamylase deficiency 
or the Sly syndrome.  
d. Fibrosis, cirrhosis and cancer 
Fibrosis, cirrhosis and cancer in the liver are often a consequence of an infectious 
disease or alcohol consumption. Viral diseases (especially hepatitis B, C and less frequently 
D) can lead to the development of chronic liver disease and hepatocellular carcinoma (HCC) 
[20], which resulted in 2015 in 720 000 and 470 000 deaths worldwide respectively [15]. HCC 
can also occur without known previous infections and be the result of NAFLD or alcoholic 
hepatitis [20]. 
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For alcoholic hepatitis, abstinence is obviously the cornerstone of treatment. Left 
untreated the disease evolves to fibrosis and cirrhosis. The latter is the eighth most common 
cause of mortality in the United States.  
e. Targeting the hepatocytes 
In all these liver diseases, the root cause starts with the hepatocyte making it often the 
target cell for therapeutic intervention. While affecting millions of people, there is nevertheless 
a lack of pharmacotherapy especially for hepatitis B, hepatocellular carcinoma and non-
alcoholic steatohepatitis and in some cases resistance to medication (e.g. anti-malaria drug 
resistance) [17]. Regarding genetic disorders, the treatment often relies on RNAi or gene 
editing technologies [3, 21] which have low cell permeability or accumulate in tissues that are 
not targeted, such as nucleic acid therapeutics [4], leading to safety liabilities. Therefore, the 
scientific community searches for new therapeutic and targeting strategies against liver 
diseases. These targeting approaches offer the opportunity to concentrate targeted drugs into 
the hepatocytes while reducing their distribution in others organs. 
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Table 1: Summary table outlining the incidence or prevalence and recommended treatment for 
hepatic diseases affecting the hepatocytes with different etiology. 
Diseases Prevalence/incidence Treatment 
Infectious diseases   
Malaria 212 million cases and 429 000 
deaths worldwide [17]  
Artemisinin-based combination therapy [22] 
Unfortunately resistance to treatment is 
emerging. 
Hepatitis A 2500 new cases per 100 000 
population in the USA in 2014 
[23] 
Vaccine. No treatment is usually necessary [24] 
Hepatitis B 850 000 to 2.2 million affected 
persons in the USA in 2014 [23] 
257 million globally in 2015 
[15] 
No treatment available for acute hepatitis B. No 
cure is available for chronic hepatitis B but 
treatment can slow the progression of cirrhosis 
and improve survival rate [25]. 
Hepatitis C 3.5 million affected persons in 
the USA in 2014 [23] and 71 
million globally in 2015 [15] 
Not always required. Until recently, treatment 
was based on interferon and ribavirin. New 
treatment is available: direct antiviral agents 
(DAA) [26]. 
Cancer   
Hepatocellular 
carcinoma 
470 000 deaths worldwide in 
2015 [15] 
5th most common cancer and 3rd 
most common cause of death 
[20] Etiology often attributable 
to hepatitis B or C. 
Resection, liver transplantation, percutaneous 
ablation however treatment is not standardized 
[27]. Only available medical therapy is Sorefanib 
which is considered only as a palliative treatment 
[28] 
Focal nodular 
hyperplasia 
(benign) 
0.8% of the adult population 
with a 10:1 female to male ratio 
[29] 
Usually static lesion. Often treated 
conservatively [30] 
Metabolic diseases   
Non-alcoholic 
fatty liver disease 
(NAFLD) and 
Non-alcoholic 
steatohepatitis 
(NASH) 
25.24% NAFLD worldwide 
prevalence with the highest 
prevalence in the Middle East 
[31]. 20-30% NASH in Western 
countries and 5-18% in Asia 
[32].  
Lack of effective treatment [33]. 
Alcohol induced 
hepatitis 
5 million in the USA, 500 000 in 
Italy [34] 
Abstinence is the cornerstone of treatment. For 
patient with acute hepatitis corticosteroid 
treatment is the standard of care. [35] 
Genetic disorder   
Wilson's disease 1 in 30000 people [36] Life-long treatment. Lack of high-quality 
evidence to estimate the relative treatment effects 
of the available drugs. Chelation therapy 
(penicillamine, trientine) or mettalothionein 
inducer. Liver transplantation might be needed in 
case of severe hepatitis or liver failure. [37] 
Hereditary 
hemochromatosis 
1 in 200 to 300 individuals of 
Northern European descent [38] 
Venesection 
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2. ASGPR based targeted hepatocyte imaging for estimation of remnant 
hepatic function  
The asialoglycoprotein receptor (ASGPR) expressed mainly at the cell surface of 
hepatocytes has been proposed as a target for radiopharmaceuticals soon after its discovery in 
the 70s [39-41]. The ASGPR expression level was indeed found to correlate with the number 
of healthy hepatocytes [42].  In case of liver disease, the total number of receptors is reduced 
and correlates with the severity of liver parenchymal damage, i.e. clinical grading scores such 
as the Child-Pugh score [42, 43]. Molecular imaging technique is now used for noninvasively 
evaluating the function and status of liver [44]. By assessing the number of ASGPR in the 
patient, doctors can deduced the remnant healthy liver volume and function before hepatectomy 
[45-47]. In a recent study, it was identified that a combination of receptor concentration and 
total amount is useful in evaluating the risk of postoperative liver failure [48]. Different 
synthetic ligands such as neogalactosyl albumin, galactosyl human serum albumin or 
neolactosyl human serum albumin have been used to evaluate liver function [49-52]. It was 
shown that residual functional liver volume could be assessed in a variety of diseases; see a 
non-exhaustive list in Table 2. Researchers are now evaluating the possibility to hit different 
targets to identify both residual healthy liver tissue and specific lesions as liver fibrosis or tumor 
tissue [53]. 
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Table 2: ASGPR targeting for assessing remaining functional liver 
Disease/Lesions Ligand Species Finding Reference 
Acute hepatitis 
and fulminant 
hepatic failure 
99mTc-GSA Patient SPECT: decreased liver uptake ratio 
and liver uptake density reduced in 
accordance with severity of hepatic 
damage  
[54] 
Chronic liver 
disease 
    
 125I-DTBG Patient Test on Serum: accumulation of 
desialylated glycoprotein in patients 
[55] 
 125I-ASOR galactosamine-
treated rats 
Decreased ASGPR expression and 
prolonged plasma half-life of ASOR 
[56] 
 99mTc-GSA Patient the ASGPR concentration significantly 
correlated with the clinical severity 
[57, 58] 
Cirrhotic patients     
 99mTc-GSA Patient Scintigraphy: higher blood clearance. 
Correlation between radioactivity and 
prognosis 
[59] 
 99mTc-GSA Patient Scintigraphy: evaluation of 
preoperative and postoperative hepatic 
functional reserve for hepatectomy 
[60-63] 
 99mTc[P(VLA-
co-
VNI)](tricine)2 
Normal and 
with liver 
cancer rabbits 
SPECT: new radio-ligand viable for 
assessment of hepatocyte function 
[49] 
Hyperbiliurinemia     
 99mTc-GSA Patient SPECT: good prediction of remnant 
liver function before hepatectomy and 
evaluation of changes in regional liver 
function after occlusion of the portal 
vein unilaterally 
[64] 
 99mTc-GSA rats with 
obstructive 
jaundice 
Scintigraphy: useful method to 
evaluate the liver functional reserve in 
cases with jaundice 
[65] 
Hepatic tumor     
 99mTc-GSA Patient ASGPR concentration correlates with 
hepatic function tests and differed 
significantly among groups of Child’s 
classification 
[43, 66, 
67] 
 99mTc-GSA Patient Cirrhotic patients and patients with a 
low Ro-remnant are at higher risk 
for postoperative liver failure. 
[68] 
 99mTc-GSA Patient The incidence of liver failure 
decreased inversely with increasing 
future ASGPR amount in remnant liver 
[48] 
 99mTc-GSA Patient 99mTc-GSA SPECT analysis can help 
diagnose ASGP-Roma HCC 
[69] 
Schistosomiasis 
mansoni 
188Re- glyco-
derivative 
compound 
Mice Hepatic ASGPR expression diminished 
only in 
the chronic infection stage 
[70] 
Fibrosis  Mice ASGPR could be a useful marker in 
the stage of liver fibrosis 
[71] 
GSA: diethylenetriamine pentaacetic acid-galactosyl-human serum albumin, HCC: hepatocellular carcinoma, 
DTGB: desialylated thyroxine-binding globulin, ASOOR: asialoorosomucoid, SPECT: single-photon emission 
computed tomography, 99mTc[P(VLA-co-VNI)](tricine)2: Poly(vinylbenzyl-O-b-D-galactopyranosyl-D-
gluconamide. Child: classification of patients with cirrhosis in three “functional hepatic reserve” categories. 
ASGP-Roma: HCC with increased ASGPR expression level in comparison with the surrounding liver tissue. This 
table is a result of literature search in pubmed using a combination of key words (ASGPR, scintigraphy, SPECT 
and imaging) 
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II. Receptor-mediated endocytosis and drug delivery  
1. Principles 
Receptor-mediated endocytosis is a natural occurring process for macromolecules and 
macromolecular complexes generally designated as ligands to enter cells upon binding to their 
specific transmembrane receptors. The ligands enter the cells via endocytic vesicles that fuse 
with early endosomes. Receptor-mediated delivery (RMD) exploits this endocytic pathway to 
deliver and concentrate a drug into the cytoplasm of intended targeted cells or pathogens via 
receptors expressed at the cell surface and therefore mitigating side effects in the rest of the 
body. Targeted delivery can be traced back to Paul Ehrlich’s work on chemotherapy [72] at the 
end of the IX century with what became “the magic bullet concept”. The concept is now being 
extended to personalized medicine where drug delivery is tailored to patient’s needs. However, 
despite the attractiveness of receptor-mediated drug delivery, it is only recently that drugs are 
reaching clinical trials and few drugs are used in clinical practice [73, 74].  
Drug delivery systems (DDS) are engineered technologies composed of three elements: 
a ligand, a pharmacological active substance and a linker [75]. The active substance can be 
directly conjugated to the ligand and in that case the DDS is designated as a drug-ligand 
conjugate, e.g. antibody drug conjugate. Another system, known as receptor targeted 
nanocarrier, is used when the active substance is encapsulated in a colloidal delivery system, 
e.g. nanoparticle, liposome, dendrimer or micelle. The success of the RMD relies on the 
optimization of various components, such as the receptor, the ligand and the linker but also of 
the pharmacokinetics of the DDS or its accessibility to the target site. Reviews on receptor-
targeting drug delivery have been published explaining the general concept of RMD but also 
its challenges [73, 75]. In this chapter, we review key parameters of RMD in optimizing drug 
delivery into the cytoplasm of intended targeted cells. 
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2. Optimizing receptor-mediated drug delivery 
a. Challenges related to the receptor 
Several factors related to the receptor are key for a successful delivery into targeted 
cells. The identification of the receptor expressed at the cell surface of the targeted cell is the 
first step of the development of a DDS. Selecting a receptor that is specific to the targeted tissue 
and not broadly expressed in the body is a key determinant to mitigate off-target toxicity and 
increase efficacy, as depicted in Figure 2.  
 
Figure 2: Extent and distribution of receptor expression in the body. The ideal scenario for drug 
targeting is when the receptor is highly expressed in the targeted tissue and minimally 
expressed in other tissues of the body.  
Sometimes due to physiologic barrier that prevents the drug access, such as the blood 
brain barrier, the targeted receptor is not directly located on the targeted cell but is rather used 
to get the DDS across a physiologic barrier [76]. The expression level, i.e. copy number, is also 
important to ensure that the drug is delivered in sufficient amount to produce an effect [77].   
After the binding to the receptor, internalization of the receptor-ligand complex is 
required to direct the drugs to their intracellular targets in the cytoplasm or nucleus. Receptors 
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often comprise several subunits and not all of them are necessarily involved in the endocytosis 
as demonstrated for the different epitope domains of the platelet–endothelial cell adhesion 
molecule 1 [78]. Therefore, if the DDS is not bound to the internalized epitope the DDS might 
not be internalized which prevent its delivery to the cytoplasm, see illustrated step 1 of  Figure 
3. It was also demonstrated that the sub-units have different intracellular transport within the 
cell, with some epitope more prone to prolonged intracellular residence [78, 79]. Therefore, the 
selection of the receptor and epitope influences the internalization feasibility and the 
subcellular distribution of the DDS. 
Internalization is also dependent on the size and the geometry of the DDS [80]. It has 
been demonstrated that the internalization is impaired by increasing DDS size, e.g. a size 
restriction for cellular uptake via the transferrin receptor was observed [81]. While both size 
and geometry influence the cellular uptake it is, however, difficult to predict a priori their 
impact. 
Some membrane-bound receptors shed their extracellular domains leading to a soluble 
form of the receptor available for binding in the circulation [82]. This results in a complex 
scenario where the binding to membrane-bound receptor is influenced by the level of the 
soluble form [83]. Both receptor forms levels should be taken into account when targeting the 
intended cells to accurately select the dose for a clinical response.  
29 
 
 
Figure 3: Steps to consider and/or optimize for a successful receptor mediated delivery at the 
cell level. The drug delivery system 1 (DDS1) binds to the type 1 subunits of the receptor while 
the DDS2 to the type 2 subunit. 2. The receptor-ligand complex is internalized. 3. The receptor-
ligand complex is recycled back to the cell membrane. 4. The ligands dissociates from the 
receptor. 5. The linker is cleaved. 6. The active substance escapes the endosome. 7. The active 
substance is free in the cytosol to interact with its pharmacological targets. 8. The active 
substance is degraded. 9. The receptor and ligands are degraded in the lysosomes. 10. The 
receptor recycles to the cell membrane. 11. Synthesis of the different subunits of the receptors. 
b. Challenges related to the ligand 
As for the receptor, identification of an appropriate ligand is necessary for a successful 
delivery. One of the criteria for the selection of such ligand is the affinity towards the targeted 
receptor. While high affinity is needed for an appropriate targeting, it has been shown that 
overly high affinity alters the intracellular trafficking of the receptor leading to reduction in 
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drug exposure in the targeted cells, as demonstrated for the transferrin receptor [84]. Therefore, 
optimization of the affinity towards the receptor is required for efficient targeting.  
In the case of receptor targeted nanocarrier being used for targeting, the number of 
ligands and their distribution influence the success of targeting due to their size - ranging from 
a few to several hundred nanometers - and their spherical form. It was demonstrated that 
intermediate ligand density is optimal for delivery in comparison to low and high density [85, 
86]. 
Sometimes an additional challenge lies in the ligand being immunogenic. For example, 
the first antibodies drug conjugates (ADC) developed contained mouse-sequence-derived 
amino acids and were found immunogenic. In such a case, anti-drug antibodies are produced 
in an adaptive immune response which may lead to hypersensitive reactions and alterations of 
the ADC efficacy [87]. In order to reduce these potential effects, chimeric antibodies and then 
fully humanized antibodies were developed and showed reduced immunogenic properties [88, 
89].  
c. Challenges related to the linker and endosomal escape 
Drug and ligand of the DDS are coupled via different strategies. The optimization of 
the linker relies first on ensuring its stability until the DDS binds to its target. For example, 
ADC carrying cytotoxic drugs should release the pharmacologically active substance only 
when reaching their targets. Once inside the cell, DDS are entrapped in the endosomes, some 
of which evolve in lysosomes where DDS are degraded by lysosomal enzymes. The drug needs 
therefore to reach their target location in the cell (cytoplasm, nucleus…etc.) for efficacy by 
escaping the endosomal vesicles, as illustrated by the step 6 of Figure 3. Different strategies 
have been envisaged for improving endosomal escape such as pore formation or fusion in the 
endosomal membrane and photochemical disruption [90]. 
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The cleavage of the linker between the drug and ligand might be useful or even 
necessary for endosomal escape. Linker technologies such as hydrazone linkers facilitate this 
cleavage in low pH environment [91] or in reductive conditions for disulfide-based linkers 
[92]. Sometimes a non-cleavable linker is used to release the drug only when the DDS gets 
degraded, e.g. a thioether bond was used to conjugate maytansinoids to humanized antibodies 
[93]. Therefore, the linker technology can be optimized to deliver the drug in specific location 
and under specific circumstances (step 5 in Figure 3). 
d. Accessibility to the target site 
Accessibility to the target cell is dependent on several factors such as the existence of 
a physiologic barrier. It is composed of tight junctions between cells as for the blood-brain 
barrier (BBB) limiting the passive diffusion of polar substances and most macromolecules from 
the periphery into the brain [94]. Targeting a receptor present at the surface of the BBB is a 
strategy to direct the DDS across it, e.g. targeting the transferrin receptor which allows the 
transcytosis across the BBB [95].  
When targeting a solid tumor, an additional challenge is the heterogeneous composition 
of the tumor limiting the permeation of the DDS in hypoperfused tumor areas [96]. In contrast 
to normal tissues, the vasculature structure becomes aberrant and is potentially composed of 
non-malignant cells. These cells are more prone to respond to anti-cancer treatment because 
unlike their malignant counterparts they are more stable and less likely drug-resistant cells. 
Therefore, targeting tumor neovasculature, e.g with homing peptides containing the Asn-Gly-
Arg (NGR) motif, is an interesting strategy [96]. Depending on the target site and localization 
different delivery strategies have been developed as for example local delivery obviating the 
need of targeting from the systemic circulation [97] or reducing the size of the DDS [98]. In 
the case of targeting the hepatocytes, accessibility is not an issue due to the discontinuous 
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capillaries that allows the transfer of small and large molecules from the plasma to the 
interstitial space. 
e. Pharmacokinetic challenges 
A pharmacological effect will depend on the duration and amount of the DDS that bind 
to the target, which is a function of residence time in plasma, from where it is available for 
receptor-mediated endocytosis. This DDS residence time in plasma is dependent on its delivery 
to the targeted cell but also on other clearance routes such as kidney filtration, metabolism… 
etc. As a consequence, the clearance route and extend of the DDS have a direct impact on the 
duration of effect.  
The phenomenon when the receptor influences the pharmacokinetic of the DDS is 
designated target mediated drug disposition (TMDD). It is observed when the interaction 
between the ligand and the receptor is happening at a significant extent (relative to the dose) 
and when the receptor-mediated processes (e.g. binding to the receptor) are much faster than 
all other processes (e.g., unspecific binding and clearance) [99]. In these circumstances, the PK 
will also depend on the level of receptor saturation, see section IV.3.  
III. Asialoglycoprotein receptor 
The asialoglycoprotein receptor (ASGPR) is a hepatic receptor mediating the cellular 
uptake of its endogenous ligands by RME. It has been extensively scrutinized since its 
discovery in the mid-1970s by Aswell and Morell and their co-workers [39, 100, 101]. This 
transmembrane C-type lectin is abundantly expressed on hepatocytes and minimally on extra-
hepatic cells which makes the receptor an attractive target for receptor-mediated drug delivery 
with minimum concerns of toxicity. 
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1. Physiological functions of the ASGPR 
a. Clearance of plasma glycoproteins 
It was first hypothesized that the function of the receptor was to participate in the 
elimination of plasma glycoproteins [39]. Glycosylation is one of the most common post-
translational modifications in eukaryotic cells since more than 50% of eukaryotic proteins are 
glycosylated [102]. These glycans are involved in many biological processes and alters the 
behavior of proteins, such as their solubility, biological half-life [103]. Among these glycans, 
sialic acids are a family of sugars with a shared nine-carbon backbone that are typically found 
attached to terminal positions, see Figure 4. 
 
Figure 4: Example of N-linked Glycoprotein and asialoglycoprotein structure. Proteins (in 
black) often undergo a glycosylation process linking covalently oligosaccharide chains to one 
or more of their amino acids side chains. In the case of a N-linked glycosylation, the 
oligosaccharide chain is attached to an asparagine (ASN). The oligosaccharide is composed of 
various sugars units such acetylglucosamine, glucose, mannose… etc (in blue in the figure). 
The arrangement of the monosaccharides can also vary. When plasma circulating glycoproteins 
lose their sialic acids (in yellow), the terminally attached Galactose (Gal) and N-
acetylgalactosamine (GalNAc) are exposed. GalNAc and Gal residues are recognized by the 
ASGPR and the asialoglycoproteins are rapidly cleared from the circulation. 
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It was assumed that these glycoproteins would lose their sialyl residues from their N-
linked carbohydrate chains at the end of their biological lifetime and then be internalized in 
hepatocytes via the ASGPR to be metabolized. However, several contradicting studies have 
been published. Wong and colleagues showed that the removal of sialic acids of the transferrin 
protein contributes only minimally (<5%) to the catabolic rate in-vivo in rabbits [104]. Then, it 
was also demonstrated that ASGPR is not driving the metabolism of other glycoproteins such 
as fetuin [105] or prothrombin [106].  
More recent publications focusing on specific proteins, i.e. sialic acid α2,6-Gal (Sia 
α2,6-Gal) bearing glycoproteins such as haptoglobin for example, showed an ASGPR mediated 
clearance [107-109]. In these studies, it was confirmed that, in ASGPR knock-out mice, 
transferrin plasma levels are not elevated but that haptoglobin and serum amyloid protein 
accumulate in plasma [109]. To date, evidence suggests that a wide range of Sia α2,6-Gal 
bearing glycoproteins are processed by the ASGPR for clearance purposes.  
In ASGPR knock-out studies, homozygous subunit 1 [110, 111] and homozygous 
subunit 2 [112] deficient mice conserved a normal phenotype and did not accumulate serum 
glycoproteins. This result is encouraging since for targeting purposes the receptor might be 
saturated when high doses of a targeted drug is used. The ASGPR knock-out mice studies 
mimics a permanent receptor saturation. Therefore, it means that asialoglycoproteins 
associated toxicity is not likely. 
b. Other identified physiological functions 
Several other physiological functions have been proposed. Dini and colleagues showed 
that at the onset of the apoptosis process, liver cells expose GalNAc and Gal residues leading 
to their endocytosis through the ASGPR [10]. In addition, the ASGPR is thought to be involved 
in the clearance of von Willebrand factor [113], platelets [114], IgA [115-118], low density 
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lipoprotein and chylomicron remnants [8, 119] and fibronectin [9]. From a pathophysiological 
perspective, ASGPR is thought to be utilized by hepatotropic viruses for hepatocyte entry [120-
125].  
Weigel in 1994 developed the “Galactosyl and N-AcetylGalactosaminyl homeostasis” 
hypothesis [12]. He describes that ASGPRs participate in the homeostasis of Gal and GalNAc- 
bearing glycoconjugates that are essential molecules in cell-cell and cell-matrix interactions. 
These glycoconjugates flow from tissues to the liver through the lymphatic system and are 
ultimately cleared by the hepatocytes (ASGPR) and by the reticuloendothelial system (Kupffer 
cells and macrophages). In this model, abnormal concentrations of Gal/GalNAc bearing 
glycoconjugates would disrupt tissue organization. Therefore, the ASGPR would play a role in 
the homeostasis of cell-cell and cell-matrix interactions by removing deleterious compounds 
from the circulation. Later, as later explained in III.3, Liu and colleagues identified a soluble 
form of the H1 ASGPR subunit [126]. They also find that the soluble form of the ASGPR 
(H1b/H2a) can bind asialoglycoproteins in plasma. Thus, Liu hypothesized that the H1b/H2a 
hetero-oligomer could contribute to the homeostasis of Gal/GalNAc glycoconjugates. This 
physiological role implies that if ASGPR would not be present, e.g. in knock-out mice, tissue 
disruption could be seen which would have significant safety implications. However, it was 
shown that knock-out mice conserved a normal phenotype [110, 112]. No confirmation of such 
homeostasis hypothesis has yet been published. 
2. Member of the lectin family 
The history of the discovery of lectin can be traced back to 1860 with the preliminary 
work from Mitchell SW on the venom of the rattlesnake [127]. The venom was found to 
aglutinate the red blood cells of a drop of pigeon’s blood. The lectin term was first used by 
Boyd in 1954 originating from the latin Lectus meaning choose, pick or select [128], relating 
to the research activity back at that time on blood-group status. A lectin was later defined as a 
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protein which is able to bind to carbohydrates but is neither an enzyme, nor an antibody nor a 
transport protein for free sugars (mono- or oligosaccharide) [129]. A recent paper from 
Manning JC and colleagues reviews the history and functions of the different lectins [130]. 
According to their structure the lectins have been classified in 17 different groups, from which 
the ASGPR belongs to the second category, hence his name of hepatic lectin. The ASGPR 
belongs to the group of the C-type lectin, i.e. binding only occurs when calcium is present 
[131]. It is a single-spanning membrane protein containing a signal-anchor sequence being 
targeted to the endoplasmic reticulum lumen with its C-terminal domain. It was the first 
transmembrane protein discovered and was then used for studying receptor-mediated 
endocytosis [100, 132-136].  
3. Structure and splice variants of the ASGPR 
The ASGPR is a hetero-oligomer composed of two homologous subunits, designated 
hepatic lectin form (H), in human HH1 (~46 kDa) and HH2 (~50 kDa) that are encoded by two 
genes. A 3D theoretical model of the ASGPR has been recently proposed by Massarelli and 
colleagues which is composed of two HH1 subunits and one HH2 subunit [137]. The ASGPR 
has been conserved through evolution and has been identified in different vertebrae, e.g. rabbit 
[138], chicken [139], rat [140], mice [111] and human [141]. Spiess and Lodish investigated 
the conservation of the two receptor genes during evolution [140]. They compared the human 
and the rat (R) sequences of the two subunit variants HH1/RH1 and HH2/RH2. They found 
more than 81% homology between HH1 and RH1 DNA sequences and 80% in the respective 
protein sequence. In mice (M), the homology between MH1/HH1 and MH2/HH2 has been 
found to be 78% and 65% respectively [142]. Rat ASGPR has an additional subunit, RH3 
[143]. Despite a high percentage of identical amino acids in the sequence of orthologues of the 
ASGPR, they cannot be assumed to have identical binding affinities for their ligands, as 
demonstrated for α2,6-linked sialic acid [144]. Therefore, for translation to human it is 
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recommended to assess the affinity towards the receptor and uptake kinetic in a human cell 
line. 
The two subunits are expressed in a molar ratio (HH1:HH2) of 3:1 in an hepatoma cell 
line (HepG2) [145]. The ASGPR HH1 subunit is composed of four domains, a N-terminal 
cytoplasmic domain (~40 aa), a single pass transmembrane domain (~20 aa), an extracellular 
region (~80 aa), and a functional calcium-dependent carbohydrate recognition domain (CRD) 
(~140 aa) [146]. Spiess and coworkers were first to identify different splice variants of the HH2 
subunit in HepG2 [140]. Later, three splice variants of the HH2 subunit, named H2a, H2b and 
H2c, were isolated in both HepG2 cells and normal human hepatocytes [147]. The H2a subunit 
differs from the others two in that it contains an extra pentapeptide and is responsible for 
endoplasmic retention and cleavage of the transmembrane fragment. The resulting H2a subunit 
is a 35-kDa fragment comprising the entire ectodomain of the ASGPR and is secreted in the 
medium as a soluble form of the protein [148]. H2b and H2c (formerly named L-H2) lack the 
5-aa insert and are therefore transmembrane proteins forming hetero-oligomers with H1 units. 
Both subunits are not present in the same hetero-oligomeric ASGPR complexes [149] while 
having similar affinity for the asialoorosomucoid (ASOR) and uptake rate. Recently, Liu and 
coworkers identified two splice variants of the HH1 subunit, designated H1a and H1b [126]. 
The H1b is lacking a 117 nucleotide segment that encodes for the transmembrane domain. 
Similarly to H2a, H1b is secreted in the medium and have also been identified in human serum. 
Therefore, taken together these findings suggest that the ASGPR is expressed as three different 
hetero-oligomers with one of them being secreted and composed of H1b and H2a subunits. 
This secreted form of the ASGPR is thought to play a role in the Galatosyl Homeostasis 
Hypothesis [12], see section III.1. It has only been demonstrated for the human form. When 
targeting the hepatic receptor for drug delivery, it implies that some of the targeted drug might 
be bound in plasma directly and transported afterwards to the liver, as suggested by Liu and 
38 
 
coworkers in 2010 [126]. Finally, the membrane bound ASGPR is composed of either H2b/H1a 
subunits or H2c/H1a subunits [149]. The two transmembrane hetero-oligomers are thought to 
be involved in different endocytic pathways [7], see section III.6. 
4. Ligands of ASGPR and binding properties 
The receptor recognizes terminal both galactose (Gal) or N-acetylgalactosamine 
(GalNAc) residues present on the N-linked carbohydrate chains of their ligands  [6] but has a 
greater avidity towards GalNAc residues [141]. The carbohydrate recognition domain of the 
ASGPR recognized a wide variety of ligands provided they present appropriate terminal or 
penultimate oligosaccharides in their composition. Thus, glycoproteins [100], low density 
lipoproteins [8] or carbohydrates such as the arabinogalactan (galactose-based polymer) [150] 
and the pullulan (glucose-based polymer) [151] are all recognized and internalized by the 
ASGPR for elimination. 
The ASGPR binding affinity is dependent on the number of terminal sugars and their 
spacing due to simultaneous binding at different sites, referred as “cluster effect” [141, 152-
155], property which is lost when the receptor is isolated from hepatocytes or if only one 
subunit is expressed at the cell membrane in transfected fibroblast-like cell lines [154, 156]. 
Therefore, ASGPR binds to several natural ligands [157] but the binding affinity increases from 
mono- to tetra-antennary oligosaccharides [158]. Dissociation constants (𝐾𝐷), i.e. the ligand 
concentration at which 50% is bound to the receptor, are typically in the nanomolar range for 
a variety of ligands. For example, 𝐾𝐷 was found to be equal to 1.3 nM for the binding to 
asialoorosomucoid (ASOR), a typical ligand used to study the ASGPR binding and RME, to 
the human ASGPR [141] and to 2 nM for a triantennary GalNAc to the mouse ASGPR [159, 
160]. Schwartz and colleague estimated the binding of ASOR to the ASGPR in HepG2 to be 7 
nM [161]. They also measured the forward rate (𝑘𝑜𝑛) of binding to be 0.95x10
6 M-1 min-1 from 
39 
 
which we can deduce the dissociation rate 6.65x10-3 min-1 (𝑘𝑜𝑓𝑓 = 𝐾𝐷 × 𝑘𝑜𝑛). GalNAc has 
been found to be well tolerated, i.e. is not immunogenic, and to have a great affinity towards 
the receptor and was therefore largely selected in recent attempts of ASGPR targeting [162]. 
5. ASGPR expression 
a. Tissue and cell type expression 
Ashwell and Morel identified and localized the ASGPR by initial studies primarily 
focusing on the regulation of copper metabolism [39]. They used radioactive ceruloplasmin 
and found that, if the protein underwent a treatment of removal of sialic acid [163], the protein 
was rapidly cleared in the plasma in comparison with the native protein [164]. The clearance 
of the ceruloplasmin from plasma was followed by a rapid accumulation in liver. Furthermore, 
historadioautography study assessed the cellular distribution [161] of the radioactivity in the 
liver and revealed an exclusive accumulation in hepatocytes. Later, Hubard and colleagues 
performed an electron microscope autoradiography study with seven different glycoproteins 
[165]. They confirmed previous results and found that the proteins which terminate by 
galactose residues were almost exclusively bound and internalized by hepatocytes (>90%). In 
comparison, proteins terminating with either N-acetyl-glucosamine or mannose were taken up 
by endothelial or kupffer cells. The ASGPR was therefore thought to be hepatocyte-specific. 
The Ashwell receptor was also found in kidney cells [166] and rat testis [142, 167] and its 
mRNA transcript was found in discrete brain regions and thyroid [168], in peripheral blood 
monocytes [169] and in most rat tissues during development [170]. However, the receptor or 
mRNA was found several fold less expressed than in the hepatocytes. Therefore, there is a lot 
of evidence for specific expression in hepatocytes. The receptor has also been identified in the 
intestinal cell line HT-29 [171], in Caco-2 cells [172] and in a hepatoma cell line (HepG2) 
[173]. In the hepatocytes the ASGPR is expressed along the entire plasma membrane, but most 
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abundantly (85% of the receptors) at the sinusoidal domain, i.e. the part of the membrane facing 
the fenestrated capillaries in the liver [174]. Thirty (rat hepatocytes) to forty (human 
hepatocytes) percent of the ASGPR is expressed at the cell surface, the remaining 60-70% are 
located intracellularly of which 35% are functional and can be used of recycling [174]. 
b. Absolute quantification 
The ASGPR expression has been first estimated in-vitro, in HepG2, where 150 000 
binding sites were found [161]. In hepatocytes and in-vitro, a wide range of values for the 
receptor number per hepatocyte is reported in the literature (0.5x105 to 1.5x106 
receptors/hepatocytes) [138, 158, 175]. In all these in-vitro studies, 125I radiolabeled ligands 
were used and direct binding assays were performed for the estimation of the receptor 
expression. The results were found variable due to cell perfusion, hepatocytes isolation or in-
vitro conditions which can impair the receptor expression at the cell surface [159]. For 
example, Hardy and coworkers demonstrated that the choice of the ligand influences the 
outcome of the measure potentially due to different cluster effect (binding to a lattice of 
ASGPRs) [138]. Weigel and Oka demonstrated that the temperature of the culture markedly 
modulates the number of receptor at the cell surface [175]. The expression level of the ASGPR 
is governed by the equilibrium between its production and degradation. The ASGPR 
degradation rate has been estimated to be between 12 and 20h in-vitro [176, 177]. 
The receptor density has also been estimated in-vivo using a radiolabeled ASGPR 
ligand, galactosyl human serum albumin. In rats, the receptor concentration was estimated to 
be 0.683 uM or 0.254 nmol/g of liver [178]. In healthy humans, the receptor concentration is 
very similar to was has been estimated in rats and is around 0.736-0.792 uM [57, 68]. Miki and 
colleagues converted the total amount of receptors into 1.09 receptors per hepatocyte [42]. 
Patients with liver diseases show reduced ASGPR expression which interestingly, correlates 
well with the severity of hepatocellular damage, i.e. with clinical grading scores such as the 
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Child-Pugh score [42, 48, 57, 179-181]. Miki and colleagues demonstrated that the reduced 
expression of total receptor was due to a reduced number of healthy hepatocytes in patients 
with a hepatic disease [42]. It was also demonstrated that patients with less than 0.3-0.4 uM 
have very poor prognosis and most likely would not survive a resection of the diseased part of 
their liver [48, 57]. The use of imaging technic and kinetic modeling has been proposed as a 
tool to assess liver function [53], see section I.2.  
The ASGPR expression has been found to be upregulated during pregnancy in mice 
with a peak level of mRNA levels of both subunits at half of the gestation period [182]. Mi and 
colleagues also found that progesterone causes an increase in ASGPR expression level after 
copulation. The ASGPR is therefore modulated during the reproductive cycle [182, 183]. 
6.  ASGPR mediated endocytosis 
ASGPR mediated endocytosis (AME) has been investigated in the 80s and 90s, mostly 
in-vitro by using HepG2 cells, isolated rat hepatocytes or transfected human hepatic 
adenocarcinoma cell line (SK-Hep-1 cells). Most of the in-vitro studies were performed with 
asialo-orosomucoid (ASOR), a natural ligand of the ASGPR. Alan Schwartz in 1991 proposed 
a review of the processes and kinetics driving AME [174]. When binding to ligands, receptor-
ligand (RL) complexes accumulate in clathrin-coated pits which internalize to form endosomal 
vesicles. Soon after, the vesicles lose their clathrin coat. Then, most RL complexes dissociates 
from each other before undergoing a sorting process. Following the sorting process, the 
receptor goes back to the cell membrane while the ligand undergoes a lysosomal degradation. 
The quantitative dynamics of the model is described in section V.2. 
Later, kinetic and pharmacology studies of ASOR binding and internalization led 
Weigel and coworkers to the conclusion that two distinct endocytic pathways drive the 
internalization of the asialoglycoprotein, designated as State 1 and State 2 pathways [7, 184].  
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A schematic representation of the two pathways can be found in the Figure 5. The endocytic 
pathways are thought to be involved two different transmembrane hetero-oligomers, composed 
of H2b/H1a subunits (State 1) or H2c/H1a subunits (State 2) [7]. Both pathways internalize the 
ligand in a clathrin coated pit but the dissociation process between the receptor and the ligand 
differs. The dissociation step is happening significantly faster (~ 2.5min) in the State 2 pathway 
than in the State 1 (~ 50min). In the State 2 pathway, the receptor dissociates from its ligand in 
an inactive form that requires a palmitoylation, i.e. covalent attachment of fatty acids, and 
reactivation step before recycling to the cell surface. In the State 1 pathway, the receptor 
recycles back to the plasma membrane without undergoing inactivation/reactivation processes. 
The recycling of the receptor-ligand complex at the cell surface, is only present in the State 1 
pathway. ASGPR is distributed in a 1:1 ratio between the 2 state pathways, but because in the 
State 2 the RL complexes dissociated much faster it is described as the major pathway 
accounting for ~80% of ligand internalization and degradation. However, in SK-Hep-1 cells it 
was demonstrated that in both pathways receptors show similar affinities towards ASOR and 
internalized the asialoglycoprotein at a similar rate [149]. This dual pathway has mostly been 
described qualitatively and little information is known on quantitative processes.  
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Figure 5: Two ASGPR mediated endocytosis pathways, adapted from Weigel and coworkers 
[7]. 1. The ASGPR ligand binds to the receptor composed of different subunits depending on 
the pathway. 2. The receptor-ligand complex is internalized. 3. The receptor-ligand complex is 
recycled back to the cell membrane (only demonstrated in the state 1 pathway). 4. The ligands 
dissociates from the receptor with different half-life, much faster in the state 2 pathway leading 
to inactive form of the receptor. 5. Palmitoylation of the receptor resulting to an active form 
(only in the state 2 pathway). 6. The receptor recycles to the cell membrane. ASGPR is 
distributed in a 1:1 ratio between the 2 state pathways. In this depicted model of RME, the 
degradation of the ligand, the synthesis and the degradation of the receptor are missing. 
The existence of a soluble and circulating ASGPR has been demonstrated in HepG2 
cell supernatant and can be detected in human serum [126, 185]. The concentration of this 
soluble form has been measured to be 0.4 µg/L in human serum which can be converted in 0.1 
nM (molecular weight of 40 kDa) [185]. The soluble form concentration is therefore very 
small, i.e. 700 fold less concentrated than the membrane bound ASGPR concentration in liver 
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(0.736-0.792 uM). Therefore, it is unlikely that the soluble ASGPR participates significantly 
in the hepatic endocytosis of asialoglycoproteins. For targeting purposes, it also means that the 
soluble form can only bound a limited DDS concentration, at maximum 0.1 nM.  
IV. General considerations for pharmacokinetics and pharmacodynamics  
1. Pharmacokinetics and pharmacodynamics definitions 
Pharmacokinetics (PK) describes and explains the concentration-time course, also 
designated as PK profile, of the compound in plasma and tissues which is dependent on 
absorption, distribution and elimination processes. PK is influenced by the physicochemical 
properties of the drug and the route of administration. Small and large molecules differ in their 
molecular weight, typically 1 kDa vs 150 kDa for therapeutics antibodies, and 
pharmacokinetics in several aspects. Small molecules, often administered orally, are eliminated 
by liver metabolism and renal excretion. In contrast, therapeutics proteins are frequently 
administered intravenously or subcutaneously and do not penetrate cell membrane easily. They 
have different elimination routes leading to half-lives ranging from hours to weeks. 
Oligonucleotides and RNAi therapeutics in general do not belong to any of these two classes 
of molecules. Oligonucleotides distribute in a large extent in tissues, especially so in kidney 
and liver, where they are taken up by cells via endocytosis [186, 187]. In tissues, 
oligonucleotides show long half-lives in the order of weeks [188]. 
Pharmacodynamics (PD) describes how the compound produces its therapeutic effects. 
PD response is driven by the concentration at the target site, i.e. biophase [189]. However, 
measurement of such concentrations are not always easy or at all possible, e.g. tissue 
concentrations that require technical sampling technics (biopsy, ultrafiltration, …). Instead, the 
link between the PK and the PD relies on the study of systemic concentrations, i.e. in plasma, 
which are in equilibrium with the biophase for small molecules in steady state conditions. 
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Building a PKPD relationship is important to derive a concentration range that produces a 
therapeutic response without causing any significant adverse effect, also known as therapeutic 
window. A PKPD study aim therefore to qualitatively and quantitatively describe the 
concentration profile and its link to the therapeutic and adverse response of a compound. 
2. PKPD Modeling and optimization of dosing regimen 
Mathematical modeling seeks for and quantifies relationships between variables by 
means of mathematical equations. When applied to PKPD modeling, the equations describe 
the effect-time courses resulting from a drug dose. Once the PKPD model is defined and 
parameters estimated, the model can be used for several purposes guiding the drug 
development of a compound [190-192]. This mathematical model enables for example to 
predict the dose response while changing the dosing regimen, i.e. dose level and frequency of 
administration. 
The question is to know to what are the relevant PK or PD processes to be incorporated 
in the model to accurately predict the therapeutic effect. Empirical models describe the data in 
a parsimonious way involving few assumptions. For example, empirical PK models are often 
made of compartments, i.e. representing kinetically homogenous group of molecules, that are 
not biologically meaningful. From these compartments, rates describe quantitatively the speed 
of the molecules getting in or out of the compartment. Mechanistic models in the contrary 
incorporate the necessary and known underlying biological processes that inform the PKPD 
response. Physiologically based pharmacokinetic modelling falls in the latter category by 
mathematically transcribing anatomical, physiological processes and physicochemical 
properties that influence the PK of a compound [193-195].  
Traditionally, PKPD parameters were estimated from studies in which the drug 
administration and sampling schedules are identical for all subjects. In that case, one can 
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estimate PKPD parameters from a naïve averaging of data, where values are averaged for each 
sampling time, or from a naïve pooled data, where all observed values are considering arising 
from a single individual [196]. 
Later, population pharmacokinetics was introduced by the seminal paper from Sheiner 
in 1969 [197]. Population PK estimate mean, also called typical or fixed, pharmacokinetic 
parameters, and the between individual and residual variability. Population parameters can be 
estimated using the two-stage approach which consists in fitting each individual’s data 
separately and combining individual parameter estimates to generate mean parameters. These 
methods cannot be used in the case of sparse data sampling.  In the case of sparse data, a single 
stage method or population method is more appropriate to estimate both typical and parameters 
that vary across individual in the population [198]. In general, population PK is a more robust 
statistical methodology that prevent biased parameter estimates in several situation such as 
missing data or dosing noncompliance [199]. The advantages of this method are numerous and 
include a small number of samples per individual, a potential for dosage individualization, the 
separation between inter-individual variability from the residual error (e.g. drug concentration 
measurement error)… etc [199].  
Modeling and simulation (M&S) in the drug development is first used in the preclinical 
space and aids on translation from animal to human [200].  It can also be used to predict the 
PKPD in special population, e.g. children [201]. Sheiner introduced the learn and confirm 
paradigm [192]. It emphasizes that clinical drug development should be viewed as a continuum 
where learnings from an experiment or clinical trial are included to update the PKPD 
knowledge of a compound. As several successful examples of model based drug development 
were shared, health authorities updated their guidelines especially with the introduction of the 
Food and Drug Administration Modernization Act in 1997. This act paved the way for using 
M&S analysis in combination with a single pivotal clinical trial as sufficient evidence of 
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effectiveness, alleviating the need for unnecessary clinical trials. The first concrete application 
was seen for the approval of gabapentin for the treatment of postherpetic neuralgia [202]. Very 
recently, the Food and Drug Administration (FDA) has launched a Model-Informed Drug 
Development (MIDD) Pilot Program which offers a framework for a constructive discussion 
of the application of MIDD approaches to the development and regulatory evaluation of 
medical products in development between the FDA and drug developers. Ultimately, M&S is 
a robust tool for the selection of an optimal dosing regimen, i.e. exposing the patient to an 
effective dose regimen while remaining safe. It can be considered at different levels, i.e. at the 
population level or at the individual level.  
3. Target-mediated drug disposition 
a. Principles 
Target-mediated drug disposition (TMDD) describes the phenomenon where the high 
affinity binding of a drug to its target (enzymes or receptors) impacts the pharmacokinetic 
profile of the drug [99, 203]. The principle governing TMDD is the capacity-limitation of the 
pool of target available for binding resulting in saturable processes. As a result, the PK is non-
linear across a dose range where the drug concentration reaches the target concentration. This 
non linearity versus dose can be illustrated when dose-normalizing concentration–time profiles 
of drugs exhibiting TMDD and where profiles would not superimpose. When drug 
concentrations exceed a certain critical concentration (𝐶𝑐𝑟𝑖𝑡), the target is completely saturated 
and the dose-normalized concentration time profile would superimpose, indicating that the 
plasma concentration is in a range of linearity. 𝐶𝑐𝑟𝑖𝑡 is dependent on the clearance of the drug, 
the volume of the central compartment and the synthesis rate of the target [204]. Similarly, if 
the drug concentration is below the binding dissociation constant the PK is also linear [203]. 
When non-linearity is observed, PK parameters such as apparent volume of distribution and 
clearance are decreasing with dose. If receptor-mediated endocytosis is involved after the 
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binding, the elimination of the drug through this pathway should be included in the PKPD 
analysis, resulting in two elimination pathways the target-mediated elimination and the non-
specific elimination, e.g. catabolism. 
TMDD is often observed for peptide- and protein-based pharmaceuticals (ie, large-
molecule compounds) such as interferon-beta [205, 206], thrombopoietin [207] and antibodies 
that have a very high affinity towards their target and show long plasma half-life and volume 
of distribution [208-210]. Some small molecules also show TMDD and in fact warfarin and 
angiotensin-converting enzyme were the first molecules for which TMDD was observed more 
than two decades ago [211]. Since then, additional small molecules have demonstrated non-
linear PK due to their binding towards a target, e.g. Selegiline a selective inhibitor of 
monoamine oxidase type B used for the treatment of early stage Parkinson disease, depression, 
and dementia [212]. Recently, the interest for small molecules TMDD has been renewed [213-
215]. 
b. TMDD models 
Different modeling approaches have been developed to analyze the PK of molecules 
showing sign of TMDD. First models were published to describe the PK of angiotensin 
converting enzyme inhibitors and included non-linear relationship to describe the saturable 
binding in plasma and tissues [216, 217]. Later, the seminal paper from Mager and Jusko in 
2001 proposed a semi-mechanistic model including the distribution and elimination of the drug 
and its interaction with the target, later referred as the classical TMDD model. The binding to 
the target is described with an on and off rate to form a receptor-drug complex which is 
internalized and degraded, if receptor mediated endocytosis follows the binding to the target. 
The model also comprises a synthesis and degradation of the target, see Figure 6. This classical 
TMDD model allows therefore the description of the PK but also the target dynamics, inferring 
the properties of the target from the plasma concentrations. 
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Figure 6 Target Mediated drug disposition model adapted from Mager and Jusko [99]. After 
the administration into the plasma, the drug can either distributes to the tissues or binds to the 
target forming a target-drug complex (rate constant, 𝑘𝑜𝑛). From this complex, the drug can 
either dissociates (rate constant, 𝑘𝑜𝑓𝑓)  or be eliminated, e.g. by internalization and degradation 
(RME). The target is also potentially synthetized and degraded. If the drug is administered 
differently, e.g. via sub-cutaneous administration, the model should be updated to include the 
absorption of the drug to the central compartment. Alternatively, the target might not be 
accessible from the plasma and the drug must first travel to a peripheral compartment before 
binding to the target. 
The full parameter set of the classical model is however not always identifiable with a 
typical PK data collection, e.g. collection of drug concentration only. For example, the binding 
constants (𝑘𝑜𝑛 𝑎𝑛𝑑 𝑘𝑜𝑓𝑓) may be difficult to estimate given their rapid nature in comparison 
to the time scale of other processes such as drug clearance. These parameters may then be fixed 
to in-vitro estimates or literature references. Alternatively, several approximations of the 
models have been discussed in the literature to reduce the model and therefore the number of 
parameter estimates [203, 210, 218]. Extensions of the TMDD model have also been developed 
to include multiple targets [219] or a more detailed mathematical description of the receptor 
mediated endocytosis [220, 221] for example. 
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V. Optimization of ASGPR mediated targeting  
1. ASGPR mediated targeting strategies  
To target the liver, two strategies have been developed: one using drug-ligand 
conjugates and the other using conjugated carriers. The conjugation with endogenous ASGPR 
ligands were first tested but resulted in the production of antidrug antibodies or allergic 
reactions [222, 223]. Then synthetic ligands such GalNAc or lact-homologous albumin were 
successfully used in substitution [224, 225]. In 2015, D’Souza published a review on ASGPR 
targeting strategies where past attempts of DLC and carriers are detailed [5]. In this review, 
therapeutic drugs mostly belonged to either the small or large molecule category. Only few 
nucleic acid therapeutics were identified. However, recently with the upturn of the RNA 
therapeutics no less than 43 therapeutic candidates were identified in the review from Huang 
in 2017 focusing exclusively on GalNAc-decorated nucleic acid therapeutics [162]. The later 
penetrates the hepatocytes with limited efficiency if not conjugated and are therefore ideal 
candidates for hepatocytes targeting [226, 227].  
2. Optimization of ASGPR mediated endocytosis 
ASGPR targeting offers the unique opportunity to concentrate targeted molecules into 
hepatocytes. However, receptor mediated delivery can be challenging and have been reviewed 
in a dedicated section, II. For ASGPR targeting, the receptor dynamics is a common 
denominator and has to be taken into account to optimize the delivery to hepatocytes and avoid 
the saturation of the receptor. Examples in the literature exist showing that a saturation of the 
receptor results in less distribution of the targeted drug into the liver relative to the dose and 
therefore more distribution to non-targeted tissues [173, 227, 228]. To avoid the saturation of 
the ASGPR, information on its dynamics of internalization, recycling and number of receptor 
present at the cell surface is needed.  
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First characterization of ASGPR dynamics was investigated in-vitro in a hepatoma cell 
line (HepG2) by Schwartz and colleagues in 1982 [173]. They used 125I radiolabeled ASOR at 
various concentrations and measured cell-associated radioactivity as well as internalized and 
degraded radioactivity. The mathematical model comprises an on-rate binding followed by an 
internalization step. Another reaction accounts for the dissociation of drug-receptor complex 
and the recycling of the receptor. This reduced TMDD model does not take into account the 
dissociation of the drug from the drug-receptor complex at the cell surface, nor the synthesis 
or degradation of the receptor. In addition, the number of receptor in the HepG2 cells is known 
to be reduced in comparison to hepatocytes. For all these reasons the model is of limited use 
for the prediction of the pharmacokinetics of a targeted compound in-vivo. Another 
mathematical model of internalization has been proposed by Weigel and co-workers in 1986 
where a two-state pathway was found to described best the internalization of 125I radiolabeled 
ASOR in isolated rat hepatocytes [184]. Quantitative knowledge is however very limited and 
the model too complex for extrapolation to in-vivo PK.  
An in-vivo pharmacokinetic model was developed to describe the PK of glycosylated 
albumin (Gal-BSA) in mice [227]. A Michaelis-Menten approximations of the TMDD model 
was used to quantitatively explain the liver uptake of Gal-BSA which assumes that the target 
turnover is much faster than the PK and the extent of binding to the target is relatively low 
[229]. The classical TMDD model is reduced to the minimum with only two differential 
equations and 2 parameters (𝑉𝑚𝑎𝑥 and 𝐾𝑀) assuming that the receptor, the receptor-drug 
complex and the concentration of drug bound to the target is negligible compared to the free 
drug concentration. By reducing the TMDD model to that extent, the quantitative description 
of the ASGPR dynamics is minimal. The Michaelis-Menten constant 𝐾𝑀 is described as follow: 
 𝐾𝑀 = 𝐾𝐷 . 𝑘𝑑𝑒𝑔.(
1
𝑘𝑜𝑓𝑓
+
 1
𝑘𝑖𝑛𝑡𝑒𝑟
) 
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with 𝑘𝑜𝑓𝑓 being the off binding rate, 𝐾𝐷 the binding constant, 𝑘𝑑𝑒𝑔 the degradation of the 
receptor and 𝑘𝑖𝑛𝑡𝑒𝑟 the internalization and degradation rate of the drug-receptor complex [230]. 
The Michaelis-Menten constant is therefore a composite of others. Translation of this 
parameter to other molecular entities is not straightforward as the internalization and 
degradation rate are not dissociable from the binding constants. Despite, the in-vitro and in-
vivo efforts of characterizing the ASGPR dynamics, gaps remain on the ASGPR dynamics in-
vivo. 
Thesis objectives 
 
ASGPR targeting has already been tested for the delivery of a wide range of molecules 
to the hepatocytes. Recently, with the upturn of RNAi therapeutics for which delivery to the 
target site has been identified as a bottleneck in their drug development, the ASGPR is a 
regarded as a promising target. RME of targeted drugs comes with pharmacokinetics 
challenges and saturation of the receptor should not be underestimated. However, there is a 
lack of quantitative knowledge on the ASGPR dynamics which is necessary to predict the 
uptake of a targeted drug in the hepatocytes and optimize the drug dosing regimen to avoid 
saturation of the receptor. 
In this context, we here present two papers which were devoted to shedding light on 
ASGPR dynamics and optimization of dosing regimen for ASGPR targeted drugs. We take 
advantage of a newly developed anti-ASGPR antibody (ASGPR Ab) and mathematical 
modeling to infer the uptake properties of the receptor in vivo in mice. The ASGPR Ab was 
injected in mice and by use of mathematical modeling, we estimated, from Ab plasma 
concentration time profile, the receptor concentration, binding kinetics, internalization and 
degradation rate of the receptor. To ensure, that the antibody was indeed targeting only the 
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receptor present at the cell surface of the hepatocytes, a second study was performed where 
radioactive Ab were injected and tissues harvested. Radioactivity was mainly recovered in the 
liver but decreased with increasing dose due to receptor saturation. The kinetics of the ASGPR 
shows that saturation of the shuttle at therapeutic concentrations is possible; however, 
simulation allows the dosing schedule to be optimized. The developed TMDD model together 
with ASGPR relevant kinetic parameters can be used to support the development of therapies 
that use the ASGPR as a shuttle into hepatocytes. 
Results from in-vivo pharmacokinetics and modeling 
studies 
 
I. In-vivo assessment of the ASGPR expression level and uptake dynamics 
1. Summary 
Various nucleic acid therapeutics that bind ASGPR are already in clinical development, but 
this receptor-mediated delivery mechanism can be saturated, which will likely result in reduced 
selectivity for the liver and therefore increase the likelihood for systemic adverse effects. 
Therefore, when aiming to utilize this mechanism, it is important to optimize both the 
administration protocol and the molecular properties. We here present a study using a novel 
ASGPR-targeted antibody to estimate ASGPR expression, turnover and internalization rates in 
vivo in mice. Using pharmacokinetic data (intravenous and subcutaneous dosing) and an in-
silico TMDD model, we estimate an ASGPR expression level of 1.8 million molecules per 
hepatocyte. The half-life of the degradation of the receptor was found to be equal to 15 hours 
and the formed ligand-receptor complex is internalized with a half-life of 5 days. The kinetics 
of the ASGPR shows that saturation of the shuttle at therapeutic concentrations is possible; 
however, simulation allows the dosing schedule to be optimized. The developed TMDD model 
54 
 
can be used to support the development of therapies that use the ASGPR as a shuttle into 
hepatocytes. 
2. Paper I 
The paper “Capacity limits of asialoglycoprotein receptor-mediated liver targeting” has been 
published in the journal “mAbs” : MAbs. 2017 Nov/Dec;9(8):1360-1369. 
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3. Supplementary material 
a. Appendix 1: Generation and in-vitro characterization of an ASGPR-
targeting antibody 
Generation of the ASGPR1 antigens and selection of specific antibodies by phage 
display 
For the generation of ASGPR1-specific antibodies, fragments of this type 2 
transmembrane protein were linked via a 3-fold G4S linker to the C-terminal end of an IgG1 
Fc. In one plasmid, the DNA sequence of the complete extracellular domain (ECD) of ASGPR1 
(amino acid positions 61-278) was fused in frame to the 3’ end of an Fc (Fc-ECD). In a second 
plasmid, the sequence of the C-type- lectin domain was deleted and only the extracellular stalk 
region necessary for ASGPR oligomerization (position 61-152) was cloned in frame 
downstream of the Fc-encoding sequence (Fc-stalk). Antibodies specific for the stalk region 
are expected not to compete with the sugar-binding site of the C-type- lectin domain, and 
therefore not to block the natural ligands of ASGPR. While the Fc served as a solubility and 
purification tag after transient production in HEK293 EBNA cells, the N-terminal avi tag 
allowed in vivo biotinylation during co-expression with Bir A biotin ligase (Supplementary 
figure 1A).  
In order to exclude cross-reactivity of ASGPR1-specific antibodies to the closest 
homologue of the ASGPR receptor, CLEC10A Isoform 2, the respective Fc-based antigens 
containing either the complete ECD or the stalk region were also cloned and expressed 
accordingly (Supplementary figure 1B). After 7 days of transfection, the produced and secreted 
fusion proteins were purified from cell culture supernatants by affinity chromatography using 
Protein A affinity chromatography, followed by a size-exclusion chromatographic step. 
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Supplementary figure 1: Schematic description of antigens. (A) The DNA sequence of either 
the whole ASGPR1 ECD (red) or only the stalk (yellow) fragment was fused to the C-
terminal end of an IgG1 Fc (grey) using a 3-fold G4S linker (black). (B) The respective 
fragments of CLEC10A were cloned accordingly. All antigens were transiently transfected 
into HEK293 EBNA cells. A simultaneously co-transfected plasmid encoding biotin ligase 
Bir A allowed avi tag-specific biotinylation in vivo. 
For the generation of ASGPR1-specific binders by phage display, our multi-
framework library was used. This library displays antigen-binding fragments (Fabs) of 30 
different heavy and light chain framework combinations (6 heavy chain frameworks 
combined with 5 light chain frameworks) on phage M13. Each framework combination of 
this synthetic library is randomized in the CDR3 region of both heavy and light chain and 
was generated by overlap extension PCR cloning using randomized trinucleotide primers. 
Based on criteria outlined in the materials and methods section, clones that were ELISA-
positive on Fc-stalk and Fc-ECD but not on Fc alone were selected for further 
characterization. 
Characterization of the ASGPR1-specific binder 4F3 
Further analysis of several ELISA-positive clones revealed that clone 4F3, containing 
variable domains of an IGHV3-23 framework and an IGLV3-19 framework, showed the most 
favorable specificities among all tested clones. As such, a surface plasmon resonance (SPR) 
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measurement was performed using a purified Fab of clone 4F3. This clone, which was 
selected on the Fc-ECD antigen, binds with an average affinity of about 25 nM almost 
equally strong to both the ASGPR1 ECD and the stalk region, concluding that its epitope is 
located in the stalk region (Supplementary figure 2A, B and D). Consequently, it does not 
bind to the C-type- lectin domain of ASGPR and therefore does not compete with natural 
ligands of ASGPR (data not shown).  
In addition, binding of 4F3 Fab to the homologous protein CLEC10A was analyzed. 
While the sequence homology for the ECDs of ASGPR1 and CLEAC10A is only 58%, the 
homology between the ASGPR1 stalk region containing the 4F3 epitope and the respective 
CLEC10A sequence was even lower (41%). As expected, no cross-reactivity to CLEC10A 
was detected (Supplementary figure 2C) underlining the specificity of 4F3 for ASGPR. 
 
Supplementary figure 2: SPR sensorgrams of 4F3 Fab on ASGPR1 antigens and 
CLEAC10A. A two-fold dilution series of 4F3 Fab ranging from 100 to 6.25 nM was injected 
in horizontal orientation over flow channels vertically immobilized with (A) Fc-ASGPR1-
stalk, (B) Fc-ASGPR1-ECD, or (C) Fc-CLEC10A-ECD.While strong binding to ASGPR1 
fragments was detected, 4F3 did not interact with CLEC10A. (D) Analysis of the kinetic 
parameters and the resulting dissociation constant. 
In a next step, each variable domain of 4F3 was separately cloned into a respective 
mammalian expression vector to form a lambda light chain and an IgG1-based heavy chain 
under control of a CMV promoter. The resulting fully humanIgG1λ antibody was expressed 
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through transiently transfected HEK293 EBNA cells in serum-free medium and purified by 
Protein A affinity chromatography followed by gel filtration. 
Material and methods for the generation of ASGPR mAb and in-vitro characterization 
Cloning of recombinant soluble antigens 
For the identification of human ASGPR1-specific antibodies by phage display, human 
IgG1 Fc fusion-based antigens were generated. The DNA sequences of both the ASGPR1 
(subunit 1 of the ASGPR) stalk region (position 61-152, Uniprot P07306) and the whole 
extracellular domain (ECD) (position 61-278) were synthesized and inserted in frame into a 
mammalian recipient vector downstream of a human IgG1 Fc-coding fragment, which served 
as solubility and purification tag. A 3-fold G4S linker was inserted between the two protein 
fragments and an N-terminal Avi tag allowed specific biotinylation during co-expression with 
Bir A biotin ligase.  
Isoform 2 of C-type lectin domain family 10 member A (CLEC10A) is the closest 
homologue of ASGPR1. In order to exclude cross-reactivity of ASGPR1-specific binders to 
CLEC10A, the respective DNA fragments (stalk region: position 61-155, ECD: position 61-
292, Uniprot Q8IUN9-2) were also cloned as Fc fusion protein as described above. 
Production and purification of antigens and antibodies  
Plasmids encoding antigens or antibodies were transiently transfected into HEK 293 
EBNA cells, stably expressing the EBV-derived protein EBNA. Where necessary, a 
simultaneously co-transfected plasmid encoding biotin ligase Bir A allowed avi tag-specific 
biotinlylation in vivo. All proteins were purified using a protein A column followed by gel 
filtration. 
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Purification of Fabs  
Fab from bacterial cultures were purified for the exact analysis of the kinetic 
parameters. For each clone, a 500 ml culture was inoculated with bacteria harboring the 
corresponding phagemid and induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside at an 
OD600 0.9. Afterwards, the cultures were incubated at 25 °C overnight and harvested by 
centrifugation. After the incubation of the resuspended pellet for 20 minutes in 25 ml PPB 
buffer (30 mM Tris-HCl pH8, 1mM EDTA, 20% sucrose), bacteria were centrifuged again and 
the supernatant was harvested. This incubation step was repeated once with 25 ml of a 5 mM 
MgSO4 solution. The supernatants of both incubation steps were pooled, filtered and loaded 
on an IMAC column (His gravitrap, GE Healthcare). Subsequently, the column was washed 
with 40 column volumes. After the elution (500 mM NaCl, 500 mM imidazole, 20 mM 
NaH2PO4 pH 7.4), the eluate was re-buffered using PD10 columns (GE Healthcare). 
Generation of anti-human ASGPR1-binding fragment from a generic multi-framework 
Fab library 
Phage display selections against the stalk region or the complete extracellular domain 
(ECD) of human ASGPR1 were carried out using our synthetic Fab library consisting of 6 
heavy chain and 5 light chain framework combinations. Panning rounds were performed in 
solution according to the following pattern: 1. Pre-clearing of ~ 1012 phagemid particles using 
human IgG1 coated at 10ug/ml onto NUNC maxisorp plates to avoid Fc-binders, 2. binding of 
non-Fc binding phagemid particles from the supernatant of the pre-clearing reaction to 100 nM 
biotinylated antigen protein for 0.5 hour in a total volume of 1 ml, 3. capture of biotinylated 
antigen and specifically binding phage by addition of 5.4 × 107 streptavidin-coated magnetic 
beads for 10 min, 4. washing of beads using 5x 1 ml PBS/Tween20 and 5x 1 ml PBS, 5. elution 
of phage particles by addition of 1 ml 100 mM triethylamine for 10 min and neutralization by 
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addition of 500 ul 1 M Tris/HCl pH 7.4, 6. Re-infection of log-phase E. coli TG1 cells with the 
phage particles in the supernatant, super-infection with helperphage VCSM13 and subsequent 
PEG/NaCl precipitation of phagemid particles to be used in subsequent selection rounds. 
Selections were carried out over 3-5 rounds using either constant or decreasing (from 10-7 M 
to 2x10-9 M) antigen concentrations. In round 2, capture of antigen:phage complexes was 
performed using neutravidin plates instead of streptavidin beads. Specific binders were 
identified by ELISA as follows: 100 ul of 50 nM biotinylated human Fc-ECD, Fc-stalk, or Fc 
alone per well were coated on neutravidin plates. Fab-containing bacterial supernatants were 
added and binding Fabs were detected via their Flag-tags by using an anti-Flag/HRP secondary 
antibody. Clones exhibiting significant signals over background were short-listed for 
sequencing. 
Affinity-determination by SPR using BioRad’s ProteOn XPR36 biosensor 
Affinity (KD) of the selected clone (4F3) was measured by SPR using a ProteOn 
XPR36 instrument (Biorad) at 25 °C. ASGPR1 antigens were immobilized on NLC chips by 
neutravidin capture. For the immobilization of recombinant antigens (ligand), antigens were 
diluted with PBST to 10 μg/ml and injected at 30 μl/minute at varying contact times to achieve 
immobilization levels of 200, 400 or 800 response units in vertical orientation. For one-shot 
kinetic measurements, injection direction was changed to horizontal orientation and two-fold 
dilution series of purified 4F3 Fab (varying concentration ranges between 100 and 6.25 nM) 
were injected simultaneously at 100 μl/min along separate channels 1-5, with association times 
of 120s, and dissociation times of 240. Buffer (PBST) was injected along the sixth channel to 
provide an “in-line” blank for referencing. Association rate constants (𝑘𝑜𝑛) and dissociation 
rate constants (𝑘𝑜𝑓𝑓) were calculated using a simple one-to-one Langmuir binding model in 
ProteOn Manager v3.1 software by simultaneously fitting the association and dissociation 
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sensorgrams. The equilibrium dissociation constant (𝐾𝐷) was calculated as the ratio 𝑘𝑜𝑓𝑓 𝑘𝑜𝑛⁄ . 
Regeneration was performed in horizontal orientation using 10 mM glycine, pH 1.5 at a flow 
rate of 100 ul/min for a contact time of 30s. 
b. Appendix 2: TMDD analysis of the intravenous PK data 
 
Supplementary figure 3: PK non linearity. Observed plasma concentrations five minutes post 
dosing (IV bolus dose) for each tested dose. 
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Supplementary figure 4: Goodness of fit Plots (IV model and data). Individual (green) and 
population (red) model prediction versus observed plasma concentrations (blue circles). 
 
Supplementary figure 5: Population and individual predictions versus observed concentrations 
(blue circles). Identity line is represented in pink. 
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c. Appendix 3: TMDD analysis of the sub-cutaneous PK data 
Supplementary table 1: Final parameter estimates of the TMDD model for the ASGPR Ab after 
SC bolus 
 Population mean 
parameter 
Intersubject 
variance 
Parameter Description Units Estimate RSE (%) Estimate RSE 
(%) 
Vc Volume of central compartment mL 1.12 fixed 0.1155 fixed 
Kd  constant of dissociation nM 4.13 fixed 0.145 fixed 
koff  dissociation rate (binding) 1/day 12.31 fixed 0.0662 fixed 
Rbase baseline target concentration nM 647 fixed 0 fixed 
keRL  rate of internalization 1/day 0.139 fixed 0.0599 fixed 
kdeg turnover rate of the target 1/day 1.06 fixed 0.413 fixed 
keL  Rate of elimination from central compartment 1/day 0.449 fixed 0.302 fixed 
Q  exchange between central and peripheral 
compartment 
mL/day 20.28 fixed 0.296 fixed 
Vp volume of the peripheral compartment mL 3.79 fixed 0.58 fixed 
ka absorption rate 1/day 1.586 16 0.366 34 
b proportional error - 0.384 9 - - 
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Supplementary figure 6: Goodness of fit Plots (SC model and data). Individual (green) and 
population (red) model prediction versus observed plasma concentrations (blue circles) 
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Supplementary figure 7: Population and individual predictions versus observed concentrations 
(blue circles). Identity line is represented in pink. 
d. Appendix 4: Optimization of administration protocol for an 
oligonucleotide 
A previously published model for a 13-mer LNA gapmer oligonucleotide was used for 
simulation.1 From this PK/pharmacodynamics (PD) model, we used the compartments 
describing the plasma disposition of the oligonucleotide (sub-model 1). In order to assess the 
potential benefit of targeting the ASGPR for delivery to the liver, we assumed the 
oligonucleotide to be conjugated to a GalNAc moiety (Kd of 2 nM).2 This conjugation would 
allow the binding to the receptor and the subsequent internalization. Therefore, we coupled the 
oligonucleotide PK model (sub-model 1) to the part of the TMDD model characterizing the 
interaction with the receptor previously described (sub-model 2) to assess the outcome of the 
targeting strategy. Model and parameters are displayed in Supplementary figure 8 and 
Supplementary table 2: Parameter of the TMDD model for ApoB targeting oligonucleotide 
(assumed to be conjugated to GalNAc residue)Supplementary table 2. 
We used the oligonucleotide model to investigate how quickly the ASGPR system recovers 
from a dose challenge. The estimated concentration-time profile of the free receptor (expressed 
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as the percentage compared to its baseline level) after an IV bolus dose of 1, 5 and 10 mg/kg 
is shown in Supplementary figure 9A. The free receptors return to the baseline levels in 3 days 
at the highest tested dose (10 mg/kg). However, oligonucleotides are rarely dosed more 
frequently that once per week due to their long half-life in tissue.3 Therefore, it is unlikely that 
the frequency of dosing may impair the delivery efficiency with this compound. We simulated 
the delivery efficiency after 2 doses varying the interval between the two doses and the amount 
given, see Supplementary figure 9B. As expected the delivery efficiency is not impaired if the 
doses are administered less frequent than once every 5 days. In addition, it can be noted that, 
with this potential ASGPR-targeting oligonucleotide, the delivery efficiency can yield 68% at 
maximum. 
 
Supplementary figure 8: Schematic illustration of the oligonucleotide PK model. The non-
target related PK developed by Shimizu and colleagues1 is represented by a two-compartment 
model (in grey) including the normal linear distribution and clearance processes (sub-model 
1). The dashed compartment represents the depot compartment from which the antibodies are 
absorbed in case of subcutaneous injection. The liver is represented in the central compartment 
where the ASGPR is expressed at the surface of the hepatocytes. The interaction of the 
oligonucleotide with the receptors results in a nonlinear target-mediated elimination pathway 
(in red, sub-model 2). Binding to the ASGPR leads to the complex formation and endocytosis. 
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The receptor turn-over is also represented with a synthesis and degradation rate. All parameters 
used in the model are given in brackets. 
Supplementary table 2: Parameter of the TMDD model for ApoB targeting oligonucleotide 
(assumed to be conjugated to GalNAc residue) 
Parameter Description Units Value reference 
Vc Volume of central compartment mL 36 [231] 
Kd  constant of dissociation nM 2 [160] 
koff  dissociation rate (binding) 1/day 12.31 estimated 
Rbase baseline target concentration nM 647 estimated 
keRL  rate of internalization 1/day 0.139 estimated 
kdeg turnover rate of the target 1/day 1.06 estimated 
keL  Rate of elimination from central compartment 1/day 20.64 [231] 
Q  exchange between central and peripheral 
compartment 
mL/day 144 [231] 
Vp volume of the peripheral compartment mL 29 [231] 
ka absorption rate 1/day 204 [231] 
 
 
Supplementary figure 9: Optimization of protocol administration for an ApoB targeting LNA 
gapmer oligonucleotide. (A) Delivery efficiency after two consecutive doses IV, varying the 
total amount and the interval between doses. The interval between the two consecutive doses 
is expressed in days and the dose in mg/kg. Contour lines represent equivalent percentage. (B) 
A B 
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Simulated free available receptor concentrations over time in mice after IV bolus. Simulated 
doses are indicated in mg/kg besides each simulation. 
e. Appendix 5: TMDD model equations 
The rate of change of the concentrations (𝐶𝑐, plasma concentration and 𝐶𝑝, tissue 
concentration) and the depot amount (𝐴𝑑) are given by the following equations.  
𝑑𝐴𝑑
𝑑𝑡
=  −𝑘𝑎. 𝐹. 𝐴𝑑 
𝑉𝑐.
𝑑𝐶𝑐
𝑑𝑡
=  𝐹. 𝑘𝑎. 𝐴𝑑 − 𝑘𝑒𝐿 . 𝐶𝑐. 𝑉𝑐 − 𝑄. (𝐶𝑐 − 𝐶𝑝) − 𝑉𝑐. 𝑘𝑜𝑓𝑓 . (𝐶𝑐.
𝑅
𝐾𝐷
− 𝑅𝐿) 
𝑉𝑝.
𝑑𝐶𝑡
𝑑𝑡
=  𝑄. (𝐶𝑐 − 𝐶𝑡) 
𝑑𝑅
𝑑𝑡
=  𝑘𝑑𝑒𝑔. (𝑅𝑏𝑎𝑠𝑒 − 𝑅) − 𝑘𝑜𝑓𝑓. (𝐶𝑐.
𝑅
𝐾𝐷
− 𝑅𝐿)  
𝑑𝑅𝐿
𝑑𝑡
=  𝑘𝑜𝑓𝑓 . (𝐶𝑐.
𝑅
𝐾𝐷
− 𝑅𝐿) −  𝑘𝑒𝑅𝐿 . 𝑅𝐿 
 
II. Tissue distribution of ASGPR radiolabeled antibodies 
The manuscript is intended for publication and will be submitted in the journal “mAbs”. In 
this journal the format is structured with the results being presented before the material and 
method. For simplicity, the same format is presented in the thesis. The running title is the 
following: “Quantitative biodistribution of radiolabeled antibodies targeting the 
asialoglycoprotein receptor in mice”. The authors who contributing to this paper are: Charlotte 
Bon, Didier Concordet, Nicolas Frances and Hans Peter Grimm.  
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1. Summary 
The asialoglycoprotein receptor (ASGPR) is a hepatic receptor mediating the uptake of 
asialoglycoproteins from the plasma circulation. Hence, the ASGPR is regarded as a promising 
receptor for drug delivery to the liver. In a previous paper we combined a pharmacokinetic 
study using an ASGPR targeting antibody and modeling to estimate key parameters of ASGPR 
mediated endocytosis processes and receptor expression. However, liver concentrations were 
not available. We therefore performed a biodistribution study to confirm the inferred liver 
uptake. To measure the antibody in tissues, the ASGPR Ab was radiolabeled with two labels 
111Indium-DOTA complex (111In) and Iodine-125 (125I). The present paper confirms the 
high and specific liver uptake of the ASGPR Ab in the liver. We captured the PK and liver 
uptake simultaneously in a refined ASGPR mediated disposition (AMD) model. By exploiting 
the mechanistic nature of this model we then explored favorable conditions for ASGPR 
targeting across different dosing regimen and different molecular elimination rates. To guide 
the optimization, we established two concepts of “targeting efficiency” and “targeting 
intensity” to emphasize on the difference between achieving high exposure in target tissue and 
mitigating off-target distribution. We believe that the AMD model can support the development 
of therapies that use the ASGPR as a shuttle into hepatocytes, from compound selection to 
dosing regimen selection. 
2. Manuscript of the second paper 
a. Introduction 
As described by German Nobel Laureate Paul Ehrlich at the end of the IX century, 
targeting drugs are the “Magic Bullets”[72] of medicine. They interact specifically with 
intended targeted cells or pathogens via receptors expressed at the cell surface mitigating side 
effects in the rest of the body. The concept has evolved through the years with the development 
of various targeting modalities such as antibody drug conjugates[1]. For targeting the liver, the 
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asialoglycoprotein receptor (ASGPR) has drawn particular attention, especially because this 
receptor is expressed almost exclusively and with high abundance [5] on hepatocytes. ASGPR 
selectively recognizes galactose (Gal) and or N-acetylgalactosamine (GalNAc) residues 
offering wide opportunities for targeting through conjugation with drug molecules. ASGPR 
targeting promises to concentrate small targeting compounds, such as such as doxorubicin 
conjugate (PK2) [232] against liver cancer, or large, such as such as the prostaglandin E1 
against fulminant hepatitis [233] in hepatocytes. The receptor is also exploited to assess the 
residual functional liver volume before hepatectomy[51] using a ASGPR receptor-based 
radiotracer. Recently, ASGPR targeting is investigated to foster the delivery of RNA 
therapeutics in hepatocytes, especially so by conjugating them with GalNAc[162, 234].  
For efficient delivery, quantitative knowledge on the receptor mediated endocytosis is 
needed to explore the targeting feasibility and optimize dosing regimen, i.e. dose level and 
dosing interval. We recently investigated the in-vivo drug delivery capacity of the receptor 
using a newly developed anti-ASGPR antibody (ASGPR Ab) in mice[13]. In this study, the 
targeting antibody showed a characteristic non-linear concentration-time profile in the plasma 
due to saturation of binding to the ASGPR and consistent with the concept of target mediated 
drug disposition (TMDD)[99]. From this, ASGPR expression and other receptor properties 
influencing the uptake such as the synthesis or internalization rates were estimated. The 
ASGPR expression was already investigated in-vitro (0.5 to 1.5 million receptors/cell[158, 
235]) and in-vivo in human (0.2 to 1.09 million receptors/cell[42, 43]). We fine-tuned the 
estimation of the expression level to 1.8 million of receptors per hepatocyte with a half-life on 
cell surface of 15 hours; and internalizing once bound with a half-life of 5 days.  
The question left unanswered is whether the inferred liver uptake can be confirmed in a 
biodistribution study which we perform in this current paper. To measure the antibody in 
tissues, the ASGPR Ab was radiolabeled with two labels 111Indium-DOTA complex (111In) 
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and Iodine-125 (125I). Intracellularly, these labels have different fates when the antibody gets 
degraded[236] and an appropriate study design and analysis can provide precious qualitative 
and quantitative information on the uptake and clearance of the antibody in the tissues[237, 
238]. In this study, we have leveraged this previous knowledge and method to design and tailor 
the biodistribution study. First the radiolabeled was administered at different dose levels to 
confirm the impact of receptor saturation on liver uptake. In order to differentiate the specific 
uptake of the ASGPR Ab from the general liver clearance of antibodies[238], a radiolabeled 
non-targeting antibody (IL17 Ab) was used as a control. Liver samples were taken at different 
times after administration to gain information on binding in the on hand (early time points) and 
cellular uptake (later time points) in the other hand. The observed liver uptake was compared 
with the predictions from the previous published TMDD model, which will be designated as 
the plasma PK model in the rest of the paper. 
Finally, we integrate the acquired knowledge to discuss how to optimize ASGPR targeting 
delivery. Two optimization criteria were proposed 1) the quantity of the drug delivered in the 
liver (targeting intensity) and 2) the percentage of the drug delivered to the liver (delivery 
efficiency). Combining the two criteria, we demonstrate that PK but non-target related or 
molecular properties influence the liver uptake. Both criteria together with the ASGPR 
mediated drug disposition model inform on what PK parameters or molecular properties need 
to be considered for a tailored drug dosage regimen and provide guidance on compound 
selection.  
b. Results 
i. Radiochemistry 
ASGPR Ab and IL17 were successfully labelled with 111In using macrocyclic chelation 
technology in the one hand and an iodogen method to label the antibodies with 125I in the other 
hand. 111In-Ab and 125I-Ab were stable in buffer at 4 and 37°C and in mouse plasma at 37°C 
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up to 120 hours (see Supplementary tables 3 to 5). In addition, cold labeled antibodies show 
non modified ability to bind the FcRn receptor in comparison to non-conjugated antibodies and 
their retention time in heparin column were also found unchanged. Finally, the cold labeled 
targeting antibody was also found to have similar binding capacity to the ASGPR in 
comparison to non-conjugated ASGPR Ab. The characteristics of the 111In and 125I ASGPR 
Ab solutions can be found in the Supplementary table 6.  
ii. ASGPR Ab binds specifically in the liver in comparison to a 
non-targeting antibody  
To assess if the ASGPR Ab were indeed distributing predominantly in the liver, we first 
investigated the distribution of the labeled antibodies 30 minutes after the IV injection, a time 
frame where binding to the receptor has already happened. We also compared the distribution 
of the radiolabeled ASGPR Ab to a radiolabeled non-targeting antibody (IL17 Ab). Thirty 
minutes after injection and regardless of the radiolabel, the relative liver uptake (expressed as 
percentage of injected dose per gram of tissue, % ID/g) is much higher than in other organs 
where only 10% ID/g was found at maximum, see Figure 7 and Supplementary figure 10. 
In addition, the liver uptake of ASGPR Ab is highest at low doses and declines with 
increasing doses. For example, 30 minutes after binding, at 1 versus 30 mg/kg, we calculate 
that 87% and 20% are found in the liver, respectively (assuming 1.2g liver weight per mouse). 
This means that almost the integrality of the dose can be taken up by the liver. The dose 
normalized plasma concentration (%ID/G) in the other hand is increasing with dose, e.g. 30 
minutes after a 1 mg/kg IV dose only 5%ID/g can be found in plasma while 60 %ID/g after a 
30 mg/kg IV dose.  
In comparison to the ASGPR Ab, the non-binding antibody (IL17) shows a limited liver 
uptake (5 %ID/g at 10mg/kg) and a high plasma concentration (82%ID/g). The IL17 Ab liver 
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uptake is lower than for the highest saturating dose of the ASGPR Ab and show how the 
targeting Ab uptake would resemble in case of extreme receptor saturation (Figure 7). 
The observed liver uptake minutes after the IV injection is therefore specific to the 
ASGPR, dose dependent due to receptor saturation and much higher than in other organs. We 
finally compared the observed liver uptake of the ASGPR Ab to the predictions from the 
plasma PK model (previous published TMDD model [13]), see Supplementary figure 11. The 
relative liver uptake is well in line with the PK-based predictions, indicating that the ASGPR 
expression in liver and the receptor saturation were previously well estimated.  
 
Figure 7: Distribution of 111In radiolabeled IL17 and ASGPR antibodies in tissue. (A) Tissue 
distribution of IL17 and ASGPR after a single IV dose of 10 mg/kg at 0.5h. A large cumulative 
uptake of 111In ASGPR Ab in liver is observed in comparison to other organs. In comparison, 
the IL17 Ab poorly distributes in tissues and remains mostly in the plasma.  (B) Dose dependent 
tissue distribution of 111In ASGPR antibodies 0.5h post IV injection. Non-specific distribution 
of IL17 Ab mimics a very high dose of ASGPR Ab where the receptor would be completely 
saturated. The distribution of 125I radiolabeled IL17 and ASGPR antibodies in tissue is 
available in Supplementary figure 10.  
iii. Kinetics of radiolabeled ASGPR Ab liver uptake 
The binding of the ASGPR Ab to the liver confirmed, we investigated the kinetics of 
the radiolabeled antibodies over time (Supplementary figure 12 and 13). At 1 mg/kg and 
following the quick distribution and binding of the ASGPR Ab in the liver, the 111In 
radioactivity in tissues is declining see Figure 8 and Supplementary figure 14. At higher doses 
(5, 10 and 30 mg/kg) the 111In radioactivity is increasing before decaying. The higher the dose 
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the longer the time to Imax, maximal concentration (%ID/g). For all doses, after half an hour 
the 125I radioactivity is continuously and significantly decaying reaching e.g. 5 %ID/g 8 hours 
post dose. The observed uptake kinetic is in line with the general trends anticipated from the 
plasma PK model prediction, however, after the initial phase of uptake, tissue uptake is largely 
over predicted (Supplementary figure 14), hinting at additional mechanisms.  
 
Figure 8: Liver and plasma radioactivity (%ID/g) over time and model prediction in mice after 
IV bolus dosing. Round markers represent individual measurements for 111In and square 
markers represent individual measurements for 125I. Lines represent the developed model 
predicted values for the tested doses, straight and dashed lines for 111In and 125I, respectively. 
The model parameters used for simulations are presented in Table 4. 
iv. Further investigations on radiolabeled ASGPR antibody 
stability 
As the kinetics of radiolabeled ASGPR Ab was not well anticipated, we investigated 
whether the radioactivity observed in the liver represents the antibody or whether some 
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mechanism of dissociation could explain this finding. In vitro it was demonstrated that the 
radiolabeled antibodies are stable in buffer and plasma up to 120 hours at 37°C (see 
Supplementary table 3 and 4).  Then we performed a trichloroacetic acid (TCA) precipitation 
to verify whether the radioactivity is still attached to protein in vivo, see Table 3. A loss of 
protein-bound radioactivity was observed for two investigated doses (1 and 30mg/kg) 
demonstrating a significant release of free 125I in the plasma.  This loss was significantly larger 
for the small dose with 22% remaining protein-bound radioactivity at 6 hours indicating a 
saturable process. Taken together these results indicate a specific uptake of 111In and 125I-
ASGPR Ab in the liver followed by a dissociation of the radiolabel and its subsequent release 
in the plasma.  
Table 3: Percentage of protein-bound 125I radioactivity in plasma 
 1 mg/kg 30 mg/kg 
0.083h 93.36 ± 0.85 96.51 ± 0.28 
0.5h 40.88 ± 1.65 97.15 ± 0.09 
6h 21.77 ± 2.89 - 
8h - 92.00 ± 0.62 
32h - 92.69 ± 0.43 
 
v.  ASGPR mediated biodistribution model in plasma and 
liver  
We extended the previous plasma PK model to describe the radiolabeled ASGPR Ab 
plasma PK and the liver uptake data simultaneously, referred as the ASGPR mediated 
disposition (AMD) model (see Figure 9 for the illustration of the model and section II.6 for the 
equations). Extensive evaluation and optimization were carried out on parameters estimation 
and on mechanistic processes included in the model. The following processes governing the 
fate of the radiolabels were found to be essential to describe plasma and liver concentrations. 
The first processes describe the fate of the labels after the intracellular degradation of the 
antibody. The degradation of the antibody leads to the release of both radio-markers 
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(degradation rate, 𝑘𝑑𝑒𝑔) as already described in the literature [238, 239]. The 125I radiolabels 
are released from the cells (assuming immediate effect) and return to the plasma circulation 
whereas the 111In radiolabels remain in the cells before degradation (degradation rate, 𝑘𝑑𝑒𝑔𝑀). 
The second process describes the dissociation of both labels after the binding of the antibody 
(𝑘𝑟𝑒𝑙125 and 𝑘𝑟𝑒𝑙111). Once released from the cells, the free radiolabels are circulating in plasma 
and therefore contribute to the radioactive signal. These free 125I plasma concentrations are 
described by a 2-compartment model whereas only one compartment model was enough to 
describe the pharmacokinetics of the 111In radiolabel, see fig. 3A. It was also assumed that 
125I radiolabels would distribute in the liver, as already demonstrated by Spetz and colleagues 
[240]. Therefore, we estimated that a part (𝛽) of the peripheral compartment would contribute 
to the radioactivity in liver. Equations are provided in section II.6.  
In the liver, the AMD model captures well the maximum and the following decline in 
concentrations regardless of the dose level and of the nature of the label. Model evaluation 
shows that the parameters were estimated with high confidence (see Table 4). Goodness of fit 
plots are provided in Supplementary figure 15 and the plasma data from the previous 
publication and new model-fit profiles plot is provided in Supplementary figure 16. 
This study confirms previous estimations of pharmacological relevant parameters 
associated with the ASGPR endocytic pathway, such as the internalization half-life, as well as 
molecular properties of the antibody such as the dissociation constant (𝐾𝐷). A comparison with 
the plasma PK model shows indeed generally good agreement with 0.75 to 1.16-fold difference 
between the two estimations (Supplementary table 8). Moreover, the semi-mechanistic 
description of underlying biological processes remains unchanged despite inter-study 
differences that have been introduced for the receptor concentration at baseline (𝑅𝑏𝑎𝑠𝑒) and the 
free receptor turn-over rate (𝑘𝑜𝑢𝑡). It is worth noting that the estimated pool of receptors was 
entirely needed to describe the liver uptake. In other words, all ASGPR belong to the liver. 
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However, parameters describing the PK of the free labels were estimated with less confidence. 
Moreover, there is a clear misfit of the 125I radioactivity in plasma at 30 mg/kg where 
radioactivity is under predicted. 
 
 
Figure 9: Schematic illustration of the ASGPR mediated disposition model. (A) The antibody 
non-target related PK is represented in the top by a two-compartment model (in grey) including 
linear distribution and clearance processes. The liver is represented in the central compartment 
where the ASGPR is expressed at the surface of the hepatocytes. The interaction of the 
antibodies with the receptors results in a nonlinear target-mediated elimination pathway (in 
red). Following the binding, antibodies lose their radiolabels which are release in the 
circulation. A two compartment model (middle) was used to describe the 125I radiolabel PK. 
A one compartment model (bottom) was used to describe the 111In radiolabel PK. (B) 
Mechanistic description of the binding of the radiolabeled antibodies to the ASGPR. After the 
receptor-ligand (RL) complex formation, the complex can undergo endocytosis, dissociate or 
lose their label. Once in the cell the antibody gets degraded releasing the radiolabel. The 125I 
catabolites are expulsed out of the cells whereas the 111In catabolites remain in the cells before 
degradation. The receptor turn-over is also represented with a synthesis and degradation rate. 
All parameters used in the model are given in brackets. 
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Table 4: Parameter estimated of the biodistribution model after IV bolus of radiolabeled 
ASGPR antibodies 
Parameter Description Units Estimate RSE (%) 
V1 Ab volume of central compartment mL 1.11 6 
Kd Constant of dissociation nM 4.78 7 
koff Dissociation rate (binding) 1/day 9.22 9 
Rbase1 
Baseline target concentration nM 
772 10 
Rbase2 347* 11 
keRL Rate of internalization 1/day 0.135 4 
kout1 
turnover rate of the target 1/day 
0.81 9 
kout2 2.16* 11 
keL Ab rate of elimination from central compartment 1/day 0.41 14 
Q Ab inter-compartmental clearance mL/day 4.78 17 
V2 Ab volume of the peripheral compartment mL 2.42 9 
Vres Residual volume of plasma in liver mL 0.16 15 
kdeg Ab degradation rate 1/day 181 fixed[238] 
kdegM 111In catabolite degradation rate 1/day 0.26 fixed[238] 
krel111 111In free label release rate 1/day 0.34 4 
V3 111In volume of central compartment mL 53.8 41 
ke111 111In rate of elimination from central compartment 1/day 0.29 50 
krel125 125I free label release rate 1/day 5.18 10 
V4 125I volume of central compartment mL 2.39 29 
V5 125I volume of the peripheral compartment mL 120 39 
ke125 125I rate of elimination from central compartment 1/day 0.25 fixed[241] 
Q125 125I inter-compartmental clearance mL/day 43.2 38 
β Percentage of  free 125I concentration in peripheral 
compartment 
- 0.015 34 
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vi.  Optimization of administration protocol using the ASGPR 
mediated disposition model 
The AMD model simultaneously describes plasma exposure and liver concentration after 
ASGPR Ab IV administration based on a semi-mechanistic description of underlying 
biological processes. On this basis, it is suggested to use this model to predict and optimize the 
targeted uptake of the antibodies and other molecules into hepatocytes. The AMD model 
separates the physiological properties such as e.g. the baseline ASGPR expression and 
molecular properties such as affinity or clearance rate. This separation   allows - in principle - 
to apply the model to different molecules on the one hand or to different species including 
human on the other hand. To note, the final model includes several PK processes related to the 
radiolabels which are not needed for investigating the targeting delivery of ASGPR targeted 
drugs and have not been used for simulation purposes. 
The ASGPR targeting offers the unique opportunity to concentrate targeting molecules 
in hepatocytes. However, there is a risk to lose this advantage when saturating the ASGPR 
endocytic pathway at high doses. We introduce two new metrics (1) the delivery efficiency, 
i.e. the percentage of the dose which is internalized by the liver and (2) the targeting intensity, 
i.e. the quantity delivered to the hepatocytes per unit of time (pmol/day). In one hand, the 
delivery efficiency indicates how much of the dose is indeed delivered to the liver as opposed 
to be distributed in non-targeted tissues, i.e. giving insight on mitigation of side effects. In the 
other hand, the targeting efficiency is an indicator of concentration in the targeted tissue that 
can be compared to an efficacy threshold for example. As the ASGPR is an endocytic receptor, 
as opposed to a cell signaling receptor, the concentration of interest is the one delivered 
intracellularly and not the one bound to the receptor. Both optimization criteria were simulated 
at steady state for compounds with low to high clearance rates varying the dosing regimen 
parameters, i.e. the dosing interval and the dose intensity (administered dose divided by dosing 
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interval), see Figure 10. Regardless of the compound clearance, a dosing regimen with low 
dose intensity and at high frequency leads to higher delivery efficiency sustaining the same 
targeting intensity (Figure 10B and Supplementary figure 17). At low doses the saturation of 
the receptors is indeed less likely which favors the delivery efficiency but diminishes the 
targeting intensity. Therefore, to maintain the same targeting intensity while using low doses, 
the frequency of administration must be increased. 
The Figure 10 demonstrates the negative impact of the dose and frequency of 
administration for compounds with higher clearance rate. For these compounds when the 
ASGPR endocytic pathway is saturated, the targeting compound is rapidly cleared and 
concentration rapidly declines in the circulation. In the contrary compounds with low clearance 
rate, such as the antibody, remain longer in the plasma free for liver uptake by newly 
synthetized ASGPRs. Hence, if one would want to deliver at least half of the dose to the liver 
and sustain a liver delivery of 15 pmol/day using the antibody, the ASGPR mediated 
disposition model would predict the optimized dosing regimen to be a dose of 630 pmol with 
dosing frequency of 21 days. With a high clearance rate compound however a lower dose of 
165 pmol must be administered every 3 days to meet these specific targeting objectives which 
in a clinic setting would be cumbersome. 
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Figure 10: Influence of plasma sustainability on delivery efficiency (A) and targeting intensity 
(B) at steady state. Simulations were performed varying the dose intensity (pmol/day) and the 
frequency of administration (interval between 2 consecutives doses in days). The simulations 
were performed for 3 compounds with low clearance rate (in black, equal to the ASGPR 
antibody clearance rate, keL), medium clearance rate (in green, 3 times faster) and high 
clearance rate (in blue, 10 times faster). Percentages along the lines in the figure 6B show the 
corresponding delivery efficiency 
3.  Discussion 
The primary goal of this study was to confirm both the specific distribution of the ASGPR 
antibodies to the liver and the estimates of the ASGPR-mediated uptake parameters in vivo 
[13]. To measure the uptake of the ASGPR Ab in the liver and the distribution in other tissues, 
the antibody was radiolabeled and tissue radioactivity was quantified. A large distribution of 
the ASGPR Ab was detected in liver regardless of the label, and minor distribution was noted 
in other tissues, confirming the rapid and extensive binding of the ASGPR Ab in the liver. In 
comparison to the ASGPR Ab, the IL17 Ab, a non-specific antibody, poorly distributes in liver 
confirming the specific distribution of the ASGPR Ab into the liver.  Moreover, the distribution 
in liver was found to saturate when increasing dose indicating receptor saturation at high doses. 
In case of non-saturating dose (1 mg/kg), almost the totality of the dose (87%) was found to 
bind 5 minutes after IV administration. Therefore, it was concluded that the ASGPR-mediated 
uptake happens solely in the liver. 
The radiolabeled ASGPR Ab distribution in liver was followed over time to get qualitative 
and quantitative information on the uptake of the antibody after its rapid binding to the ASGPR. 
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As anticipated, a decline of radioactivity in the liver was observed due to antibody 
internalization and subsequent degradation. However, the extent of the decline was under-
predicted regardless of the label. A TCA assay revealed a loss of protein-bound radioactivity 
in plasma demonstrating a significant release of free 125I in the plasma in a dose dependent 
manner indicating a saturable process. We came to the conclusion that both markers dissociated 
from the antibody subsequent to the ASGPR binding. 125I release after receptor binding has 
already been described in the literature when a 125I CA125 targeting antibody distribution was 
administered to the tumor bearing mice [242]. Instability of the labels in plasma was ruled out 
in-vitro and therefore does not explain the in-vivo dose dependent release of the labels in 
plasma. An alternative interpretation would have been that the internalization rate was much 
more rapid than anticipated. However, this was found to be inconsistent with the antibody 
clearance in plasma [13]. We tested whether a model with another parameter set involving a 
higher internalization rate would explain the data but could not be found (see Supplementary 
figure 18).  
The processes governing the fate of the labels subsequent to the Ab binding were added to 
the target-mediated uptake, i.e. the dissociation of the labels and their pharmacokinetics in 
plasma. The radioactivity in plasma was explained by the signal originating from antibody 
bound radiolabels but also from the freely circulating labels. However, the final model 
demonstrated shortcomings such as the description of 125I radioactivity in plasma, especially 
for the highest dose (30mg/kg) where the observations were under-predicted. Ideally, the 
antibody metabolism rate can be estimated by modeling the difference of the signal of the two 
labels in the tissue over time [238]. However, this was not possible in our case due to the 
dissociation of the radiolabel and we had to use the rates available in the literature [238]. 
The parameters of the ASGPR mediated disposition model were well estimated and close 
to the former estimations [13] and some generic parameters, such as the residual volume in 
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liver [243],  were in line with previous findings. The concentration of ASGPR at baseline and 
its degradation rate were found to differ between the two studies by 2 to 3 fold which we 
propose to explain by the difference in body weight and by the difference in the observations 
type between the two studies, i.e. ELISA vs radioactivity measurements. 
The actual cause of the dissociation of the labels from the antibody remains unknown. 
Given the slow estimated half-life of the internalization of the receptor-ligand complex, the 
model predicts that the antibody bound to the receptor remains at the cell surface for quite some 
time before internalization and therefore we speculate that the labeled antibody is exposed to 
enzymes in the liver extracellular matrix leading to the label dissociation. Alternatively, rapid 
cycles of endocytosis and recycling of the receptor ligand complex - as demonstrated for the 
tyrosine kinase receptor ErbB2 [244] – would expose this complex to the endosomal 
environment where reduced pH (5-5.5) [245] or enzymes may cause the dissociation of the 
labels.  We found that this alternative model would also explain the observed data in plasma 
and liver (data not shown).  A recycling of the RL, if it exists, would offer an opportunity to 
increase the targeting intensity, e.g. by designing a pH-dependent binding engineering or a 
hydrazone linker between the payload and the ASGPR targeting drug [91]. A first attempt has 
been already published for delivering gene therapy to hepatocytes using pH sensitive cationic 
lipids [246]. 
Optimizing liver uptake while mitigating off-target toxicity is the primary goal of a ASGPR 
targeting strategy and should be supported by models such as the AMD model [13]. We have 
proposed to discuss delivery optimization based on two metrics: the targeting intensity (relating 
to exposure at the target site) and the targeting efficiency (relating to the selectivity of the 
uptake). Dosing regimen optimization of liver uptake has been especially discussed for 
compounds with different non-target related clearance rates. We show that low clearance and 
adequately small dosing intervals are favorable for both criteria. Conversely, achieving both 
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high targeting intensity and targeting efficiency becomes impossible at any reasonable dosing 
interval for targeting molecules with high clearance rates. The ASGPR mediated disposition 
model is therefore a tool to select a dosing regimen that maximizes the targeting intensity while 
minimizing the distribution to other organs and non-target related clearance due to receptor 
saturation. 
ASGPR targeting is also used for estimation of remnant hepatic function using radiolabeled 
ASGPR ligand and imaging technics. This technic allows the estimation of receptor expression 
in patients which has been found to be reduced and correlates with the severity of liver 
parenchymal damage. Alternatively, the ASGPR Ab could be used in combination with the 
AMD model in clinic to estimate the receptor number in patients and alleviate the need for 
radioactivity injection in patients. It has been demonstrated that using a within-individual dose 
escalation design, coined as “Espresso design”, the parameter estimation was feasible in a 
limited time frame compatible with patient hospitalization [247, 248].  
In conclusion, the present paper confirms the high and specific liver uptake of the ASGPR 
Ab in the liver. We captured the PK and liver uptake simultaneously in a refined mathematical 
model. By exploiting the mechanistic nature of this model we then explored favorable 
conditions for ASGPR targeting across different dosing regimen and different molecular 
elimination rates. To guide the optimization, we established the two concepts of “targeting 
efficiency” and “targeting intensity” to emphasize on the difference between achieving high 
exposure in target tissue and mitigating off-target distribution. We believe that the AMD model 
can support the development of therapies that use the ASGPR as a shuttle into hepatocytes, 
from compound selection to dosing regimen selection.  
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4. Material and method 
a. Radiolabeling 
Antibodies used in this paper were radiolabelled with indium-111through random 
modification of lysine residues followed by conjugation to 1,4,7,10-tetraazacyclododecane- 
N,N’,N,”N”’-tetraacetic acid (DOTA) for indium-111 (111In) complexation [239, 249]. The 
radiolabeled proteins were purified using PD-10 column (GE Healthcare Life Sciences) pre-
equilibrated in PBS. For the labelling of 125I, different methods were tested, i.e. by coupling 
of Iodoprecursor 125I-SIB (N-succinimidyl 3-125I-iodobenzoate), by use of Chloramine T or 
Iodogene as oxidant. The later was finally selected because it was the only one showing 
stability in buffer and plasma at 37°C and retaining binding capacity to the ASGPR, see 
Supplementary table 4. 
All radiolabeled antibodies were characterized by size-exclusion high performance 
liquid chromatography with in-line radiometric and UV detectors to compare the profiles of 
radioimmunoconjugates and corresponding unlabelled antibodies. In addition, stability in 
buffer at 4 and 37°C and in plasma at 37°C was tested up to 72 hours. Ab binding to FcRn, 
heparin column and finally binding to ASGPR receptor was tested.  
b. Animals and Treatments 
8-week old male C57BL/6 mice (22-26g) were used for all in-vivo studies. Animal 
experiment was conducted at Chelatec, France, and in accordance with the European Council 
Directive 2010/63/EU. Experimental plan was preliminary reviewed and approved by the local 
ethical committee “Comité d’Ethique en Expérimentation Animale des Pays de La Loire - 
C2EA-06”, and the authorization was then delivered by Ministry of Research. Before the 
antibody treatment, 1 day and 5min before dosing, mice were injected via intra-peritoneal route 
with 100 μL of sodium iodide at 30 mg/mL to prevent iodine-125 sequestration in the thyroid. 
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Then, mice received either the ASGPR targeting antibody (group 1) or a non-targeting IL-17 
antibody (group 2). 66 mice were allocated to the group 1 and received a 1, 5, 10 or 30 mg/kg 
dose bolus IV injection in the tail vein of the ASGPR Ab. 18 mice were allocated to group 2 
and received a single bolus IV injection in the tail vain at a dose of 10 mg/kg. For all studies, 
mice were fed ad libitum and kept under controlled conditions. 
c. Treatment solutions  
The solution of sodium Iodide at 30 mg/mL was prepared by dilution of the stock 
solution (Coophavet Laboratory, batch number: 6C49A1; concentration: 160 mg/mL) in 0.9% 
NaCl. The ASGPR Ab or the IL-17 solutions were prepared as a mixed of cold solution, 125I-
labeled Ab solution and 111In-labeled Ab solution in a ratio explained in Supplementary table 
7.  Each dose group was treated sequentially therefore, radiolabeling and treatment solutions 
had to be repeated before each treatment.  
d. Sample collection and analysis 
One, maximum two, plasma samples per animal were withdrawn from the 
submandibular vein from lightly anesthetized mice with isoflurane. Each blood sample was 
collected into Microvette® tubes with heparin lithium (Sarstedt®) and was then processed for 
plasma (centrifugation for 5 min at 10 000 g). Tissues samples were terminally harvested. 
Organs of interest were excised, rinsed in NaCl 0.9% of residual blood, weighed using a 
precision balance and stored at +4 °C until radiometric analysis. The selected tissues were liver, 
kidneys, spleen, stomach, skeletal, muscle and skin.  
Radioactivity counts were measured in tissue and plasma samples using a 2470 Wizard 
2 automatic gamma counter (Perkin Elmer). The 125I activity was counted in a channel with 
windows set for 15-85 keV and 111In activity was counted in a channel having windows set 
for 100-600 keV.  
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e. Pharmacokinetic and biodistribution data 
A previous pharmacokinetic study was conducted with the same ASGPR antibody to 
estimate ASGPR expression, turnover and internalization rates in-vivo in mice [13]. Using 
micro-sampling technique, up to 16 plasma samples per animal were withdrawn leading to a 
rich dataset. In contrast, in the biodistribution study only one-time point per animal, maximum 
two for plasma sampling, were obtained. Therefore, we decided to combine both datasets to 
leverage information at the plasma and tissues levels.  
Observations from the biodistribution study were radioactive counts and not 
concentrations.  We decided to fit the raw data and not back-transformed concentrations 
because of two reasons 1) the radioactivity signal depends both on the concentration present in 
the sample and on its size 2) not all radioactivity is associated with antibody (due to label 
dissociation subsequent to ASPGR binding) and thus calculation of antibody concentrations 
from radioactivity is not straight forward. Therefore, it was decided to fit the raw data, i.e. 
radioactive counts.  
f. Additional analyses of plasma samples by TCA precipitation 
150 µL of each sample and 100 µL of TCA 30% were added in 1.5 mL microtube. Tube 
was homogenized and then centrifuged for 5 min at 5000 g. The supernatant was aspirated and 
then transferred to new vial for radioactivity counting. Pellet was washed with 200 µL PBS1X 
and re-centrifuged for 5 min at 5000 g. The radioactivity in supernatant and pellet were counted 
in 125I-channel of the Gamma counter. The percentage of TCA precipitable radioactivity was 
calculated as follows: 
𝑃𝑒𝑐𝑒𝑛𝑡𝑎𝑔𝑒𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑏𝑜𝑢𝑛𝑑 𝑟𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛 𝑝𝑒𝑙𝑙𝑒𝑡
𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛 𝑝𝑒𝑙𝑙𝑒𝑡 +  𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
 
Unfortunately, the physical decay of 111-Indium being much faster than 125-Iodine, 
the same method could not be used for the determination of protein-bound 111In radioactivity. 
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Only few samples were analyzed, from the group receiving 1mg/kg at 0.08, 0.5 and 6h, and 
from the group receiving 30mg/kg at 0.08, 0.5, 8 and 32h.   
g. Software and parameters estimation  
Parameters have been estimated using a non-linear mixed-effect approach in 
MONOLIX 4.3.3. Inter-subject variability could not be estimated because only one, maximum 
two, samples were available per animal[196]. A residual proportional error model was used for 
all observation types.  
h. Simulation experiment using the refined ASGP mediated disposition 
model for optimization of administration protocol for various  
A simulation experiment was performed using the AMD model using the refined parameter 
estimates (see Supplementary table 9). First, we defined the targeting intensity as the amount 
internalized in the hepatocytes over a period of time:  
 𝐴𝑚𝑜𝑢𝑛𝑡 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑖𝑧𝑒𝑑∆𝑡 = (∫ 𝑘𝑒𝑅𝐿 ×
𝑑𝑅𝐿
𝑑𝑡
𝑡+∆𝑡
𝑡
. 𝑑𝑡) × 𝑉𝑐 
𝑇𝑎𝑟𝑔𝑒𝑡𝑖𝑛𝑔 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦∆𝑡 =  𝐴𝑚𝑜𝑢𝑛𝑡 𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑖𝑧𝑒𝑑 ∆𝑡⁄  
We also define the delivery efficiency as the percentage of the total given dose that is 
internalized via the target-mediated pathway:  
𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑦 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦∆𝑡  = (𝐴𝑚𝑜𝑢𝑛𝑡 𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑖𝑧𝑒𝑑∆𝑡 𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐷𝑜𝑠𝑒⁄ ) × 100 
By contrast, the rest of the dose that is not internalized is distributed in the rest of body 
(off-target distribution), and subsequently eliminated via unspecific mechanisms (unspecific 
clearance). Delivery efficiency and targeting intensity have been simulated at steady state 
varying the dose and the interval between two consecutive doses (∆𝑡). This simulation exercise 
was repeated for compounds with low to high clearance rates in comparison to the antibody 
clearance rate (𝑘𝑒𝐿), i.e. 1) 𝑘𝑒𝐿,  2) 3 × 𝑘𝑒𝐿 and 3) 10 × 𝑘𝑒𝐿 . 
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5.  Supplementary material 
Supplementary table 3: Radiolabeling with Indium-111 of DOTA(NHS)-ASGPR Ab 
 111In-DOTA- ASGPR Ab 111In-DOTA- IL17 Ab 
Radiolabeling yield 51.0% 47.3% 
Radiopurity 96.30% 98.79% 
Stability in buffer 
T0 (4°C) 96.30% 99.02% 
T24H (4°C) 96.18% 98.79% 
T24H (37°C) 95.16% 98.1% 
Stability in mouse plasma (at 37°C) 
T0 97.07% 98.91% 
T3H 96.20% 98.36% 
T24H 94.93% 98.74% 
T48H 95.45% 98.57 % 
T120H 95.89% NA 
Biological activity 
Functional integrity test Similar as non-labeled antibody NA 
Binding assay Similar as non-labeled antibody NA 
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Supplementary table 4: Radiolabeling with Iodine-125 of ASGPR Ab 
 125ISIB method* 
(in borate 0.2 M) 
Chloramine-T method Iodogen method 
Radiolabeling yield 50.5% 97.6% 97.9% 
Radiopurity 98.15% 99.48% 98.08% 
Stability in buffer 
T0 (4°C) 98.15% 99.48% 98.08% 
T18H (4°C) 96.92% 99.43% 98.16% 
T48H (4°C) 96.44% 99.37% NA 
T72H (4°C) 95.00% NA 97.88% 
T96H (4°C) 94.40% NA NA 
T24H (37°C) 85.15% 99.47% 98.28% 
Stability in mouse Plasma (at 37°C) 
T0 96.23% 99.26% 97.17% 
T3-5H 92.31% 99.03%  
T24H 82.08% 98.62% 97.23% 
T48H 79.99% NA  
T72H 78.24% NA 96.94% 
T120H 78.41% 97.54%  
Biological activity 
Functional integrity test NA Ab mostly oxidized, with clear 
impact on FcRn interaction 
Similar as non-labeled antibody 
Binding assay 
NA 
20-30% reduction in binding 
potency 
Similar as non-labeled antibody 
 
Supplementary table 5: Radiolabeling with Iodine-125 of IL17 Ab 
125I- IL17 Ab 
Radiolabeling yield 96.1% 
Radiopurity 96.45% 
Stability in buffer 
T0 (4°C) 96.45% 
T24H (4°C) 96.79% 
T24H (37°C) 96.27% 
Stability in mouse plasma (at 37°C) 
T0 96.15% 
T3H 96.06% 
T72H 96.24% 
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Supplementary table 6: Characteristics of 111In and 125I ASGPR Ab solutions 
 111In-DOTA- ASGR Ab 125I- ASGR Ab 
Dose group 1mg/kg 5mg/kg 10mg/kg 30mg/kg 1mg/kg 5mg/kg 10mg/kg 30mg/kg 
Mean Labelling efficiency 40.0% 39.5 45.0% 35.0% 96.7% 94.85% 96.7% 96.0% 
Concentration (µg/mL) 218.32 370.13 497.43 603.29 353.4 360.8 488.4 1068.4 
Specific Activity (mCi/mg) 
3.12 3.28 3.51 2.75 2.77 2.97 3.09 2.80 
Radiopurity 97.3% 97.3% 97.0% 95.9% 99.65% 99.39% 99.30% 99.72% 
 
Supplementary table 7: Antibody solutions preparation 
Total dose (mg/kg) 1 5 10 30 
111In-DOTA-antibody (mg/kg) 0.4 0.4 0.4 0.4 
125I-antibody (mg/kg) 0.4 0.4 0.4 0.4 
Cold antibody (mg/kg) 0.2 4.2 9.2 29.2 
This table depicts the amount of each solution (cold, 125I and 111In) that were mixed to make 
the final administration solution. The mixing scheme is the same for both antibodies, ASGPR 
Ab and IL17 Ab.  
 
Supplementary figure 10: Distribution of 125I radiolabeled IL17 and ASGPR antibodies in 
tissue. (A) Tissue distribution of IL17 and ASGPR after a single IV dose of 10 mg/kg at 0.5h. 
A large uptake of 125I ASGPR Ab in liver is observed in comparison to other organs. In the 
contrary, the IL17 Ab poorly distributes in tissues and remains mostly in the plasma at the same 
dose.  (B) Dose dependent tissue distribution of 125I ASGPR antibodies 0.5h post IV injection. 
Non-specific distribution of IL17 Ab mimics a very high dose of ASGPR Ab where the receptor 
would be completely saturated. 
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Supplementary figure 11: Observed vs prediction of the plasma PK model of the relative liver 
uptake to the dose, 5 min (at 1 mg/kg) or 30 minutes (at 5, 10 and 30 mg/kg) after IV 
injection. Predictions are well in live with observed liver uptake. 
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Supplementary figure 12: 111In-Ab tissue distribution over time 
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Supplementary figure 13: 125I-Ab tissue distribution over time 
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Supplementary figure 14: Observations versus anticipated relative liver uptake expressed as 
percentage of injected dose per gram of tissue. Model and parameters used for simulation can 
be found in the paper published by Bon et al. in 2017 [13]. 
 
Supplementary figure 15: Goodness of fit plot. Normalized prediction distribution errors 
(NPDE) are used as a metric used to evaluate the model. NPDEs test for differences from a 
perfect fit of the model to the data. Therefore, the smallest NPDEs and the homogenous 
repartition of the NPDE along the null x-axis the better.  
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Supplementary figure 16: Observed plasma PK data following non-radiolabeled ASGPR Ab 
IV (data already presented in Bon et al. in 2017 [13]) and model fit. 
Supplementary table 8: Estimated model parameters of ASGPR mediated endocytosis in both 
studies and fold differences.  
Parameter Description Units Biodistribution 
study 
PK study[13] Fold difference 
Kd Constant of dissociation nM 4.78 4.13 1.16 
koff Dissociation rate (binding) 1/day 9.22 12.31 0.75 
Rbase Baseline target concentration nM 772 647 1.19 
keRL Rate of internalization 1/day 0.135 0.139 0.97 
kout turnover rate of the target 1/day 0.81 1.06 0.76 
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Supplementary figure 17: Influence of dosing level (expressed in pmol/day) and dosing 
frequency (expressed in days between two consecutive injections) on delivery efficiency 
expressed in percentage of dose internalized by the liver (A) and delivery intensity expressed 
in pmol/day (B). 
 
Supplementary table 9: AMD model parameters used for simulations 
Parameter Description Units Estimate RSE (%) 
V1 Ab volume of central compartment mL 1.11 6 
Kd Constant of dissociation nM 4.78 7 
koff Dissociation rate (binding) 1/day 9.22 9 
Rbase Baseline target concentration nM 772 10 
keRL Rate of internalization 1/day 0.135 4 
kout1 turnover rate of the target 1/day 0.81 9 
keL Ab rate of elimination from central compartment 1/day 0.41 14 
Q Ab inter-compartmental clearance mL/day 4.78 17 
V2 Ab volume of the peripheral compartment mL 2.42 9 
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Supplementary figure 18: Would a faster internalization rate be compatible with the plasma PK 
of the ASGPR Ab? To test this hypothesis, we fixed the rate of internalization (keRL) to 
different values (fold increase from estimated value in Bon et al. 2017) and fitted the plasma 
data after non-radiolabeled ASGPR Ab IV injection. We report here the objective function of 
each fit which is an objective measure of the differences between the observed data and 
predicted values by the model.  
 
6.  Appendix: equations of the ASGPR mediated disposition model 
The AMD model is described with the following equations: 
𝑑𝑅
𝑑𝑡
=  𝑘𝑜𝑢𝑡. (𝑅𝑏𝑎𝑠𝑒 − 𝑅) − 𝑘𝑜𝑓𝑓 . (𝐶𝑐.
𝑅
𝐾𝐷
− 𝑅𝐿) − 𝑘𝑜𝑓𝑓. (𝐶𝐴𝑏111.
𝑅
𝐾𝐷
− 𝑅𝐿𝐴𝑏111) 
− 𝑘𝑜𝑓𝑓 . (𝐶𝐴𝑏125.
𝑅
𝐾𝐷
− 𝑅𝐿𝐴𝑏125) 
𝑉1.
𝑑𝐶𝑐
𝑑𝑡
=  −𝑘𝑒𝐿 . 𝐶𝑐. 𝑉1 − 𝑄. (𝐶𝑐 − 𝐶𝑝) − 𝑉1. 𝑘𝑜𝑓𝑓 . (𝐶𝑐.
𝑅
𝐾𝐷
− 𝑅𝐿) 
𝑉2.
𝑑𝐶𝑡
𝑑𝑡
=  𝑄. (𝐶𝑐 − 𝐶𝑡) 
𝑑𝑅𝐿
𝑑𝑡
=  𝑘𝑜𝑓𝑓 . (𝐶𝑐.
𝑅
𝐾𝐷
− 𝑅𝐿) −  𝑘𝑒𝑅𝐿 . 𝑅𝐿 + 𝑘𝑟𝑒𝑙111𝑅𝐿𝐴𝑏111 +  𝑘𝑟𝑒𝑙125𝑅𝐿𝐴𝑏125 
𝑉1.
𝑑𝐶𝐴𝑏111
𝑑𝑡
=  −𝑘𝑒𝐿 . 𝐶𝐴𝑏111. 𝑉1 − 𝑄. (𝐶𝐴𝑏111 − 𝐶𝑝𝐴𝑏111) − 𝑉1. 𝑘𝑜𝑓𝑓 . (𝐶𝐴𝑏111.
𝑅
𝐾𝐷
− 𝑅𝐿𝐴𝑏111) 
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𝑉2.
𝑑𝐶𝑝𝐴𝑏111
𝑑𝑡
=  𝑄. (𝐶𝐴𝑏111 − 𝐶𝑝𝐴𝑏111) 
𝑑𝑅𝐿𝐴𝑏111
𝑑𝑡
=  𝑘𝑜𝑓𝑓 . (𝐶𝐴𝑏111.
𝑅
𝐾𝐷
− 𝑅𝐿𝐴𝑏111) − 𝑘𝑒𝑅𝐿 . 𝑅𝐿𝐴𝑏111 − 𝑘𝑟𝑒𝑙111𝑅𝐿𝐴𝑏111 
𝑑𝑅𝐿𝑖𝑛111
𝑑𝑡
=   𝑘𝑒𝑅𝐿 . 𝑅𝐿𝐴𝑏111 − 𝑘𝑑𝑒𝑔𝑅𝐿𝑖𝑛111 
𝑑𝐼𝑛𝑑𝑖𝑢𝑚𝑖𝑛
𝑑𝑡
=   𝑘𝑑𝑒𝑔𝑅𝐿𝑖𝑛111 −  𝑘𝑑𝑒𝑔𝑀. 𝐼𝑛𝑑𝑖𝑢𝑚𝑖𝑛 
𝑉1.
𝑑𝐶𝐴𝑏125
𝑑𝑡
=  −𝑘𝑒𝐿 . 𝐶𝐴𝑏125. 𝑉1 − 𝑄. (𝐶𝐴𝑏125 − 𝐶𝑝𝐴𝑏125) − 𝑉1. 𝑘𝑜𝑓𝑓 . (𝐶𝐴𝑏125.
𝑅
𝐾𝐷
− 𝑅𝐿𝐴𝑏125) 
𝑉2.
𝑑𝐶𝑝𝐴𝑏125
𝑑𝑡
=  𝑄. (𝐶𝐴𝑏125 − 𝐶𝑝𝐴𝑏125) 
𝑑𝑅𝐿𝐴𝑏125
𝑑𝑡
=  𝑘𝑜𝑓𝑓 . (𝐶𝐴𝑏125.
𝑅
𝐾𝐷
− 𝑅𝐿𝐴𝑏125) − 𝑘𝑒𝑅𝐿 . 𝑅𝐿𝐴𝑏125 − 𝑘𝑟𝑒𝑙125𝑅𝐿𝐴𝑏125 
𝑑𝑅𝐿𝑖𝑛125
𝑑𝑡
=   𝑘𝑒𝑅𝐿 . 𝑅𝐿𝐴𝑏125 − 𝑘𝑑𝑒𝑔𝑅𝐿𝑖𝑛125 
𝑑𝐶111
𝑑𝑡
=  𝑘𝑟𝑒𝑙111. 𝑅𝐿𝐴𝑏111. 𝐷𝐴𝑅111 − 𝑘𝑒111. 𝐶111 
𝑑𝐶125
𝑑𝑡
= (𝑘𝑟𝑒𝑙125. 𝑅𝐿𝐴𝑏125. 𝐷𝐴𝑅125 +  𝑘𝑑𝑒𝑔𝑅𝐿𝑖𝑛125).
𝑉1
𝑉4
+ 𝑄125. (𝐶𝑝125 − 𝐶125).
1
𝑉4
 
− 𝑘𝑒125. 𝐶125 
𝑑𝐶𝑝125
𝑑𝑡
= −𝑄125. (𝐶𝑝125 − 𝐶125).
1
𝑉5
  
The amounts (in nmol) in liver are given by the following equations: 
𝐴𝑙𝑖𝑣111 = (𝐶𝐴𝑏111. 𝑉𝑟𝑒𝑠 + (𝑅𝐿𝐴𝑏111 + 𝑅𝐿𝑖𝑛111 +  𝐼𝑛𝑑𝑖𝑢𝑚𝑖𝑛). 𝑉1) 
𝐴𝑙𝑖𝑣111𝑓𝑟𝑒𝑒 = 𝐶111. 𝑉𝑟𝑒𝑠 
𝐴𝑙𝑖𝑣125 = (𝐶𝐴𝑏125. 𝑉𝑟𝑒𝑠 + (𝑅𝐿𝐴𝑏125 + 𝑅𝐿𝑖𝑛125). 𝑉1) 
𝐴𝑙𝑖𝑣125𝑓𝑟𝑒𝑒 = 𝐶125. 𝑉𝑟𝑒𝑠 
𝐴𝑙𝑖𝑣125𝑓𝑟𝑒𝑒𝑖𝑛 = 𝛽. 𝐶𝑝125. 𝑉5 
The specific activities (in µCi/µg) involved in the model are the following: 
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𝑆𝐴𝑏111 = 𝑆𝐴111. 𝑒
−𝛾111𝑡 
𝑆𝑖𝑛𝑑𝑖𝑢𝑚 = 𝑆111. 𝑒
−𝛾111𝑡 
𝑆𝐴𝑏125 = 𝑆𝐴125. 𝑒
−𝛾125𝑡 
𝑆𝑖𝑜𝑑𝑖𝑛𝑒 = 𝑆125. 𝑒
−𝛾125𝑡 
The radioactivities (in µCi) in plasma and tissues are given by the following equations: 
𝐴𝑐𝑡𝑙𝑖𝑣111 = 𝐴𝑙𝑖𝑣111. 𝑆𝐴𝑏111. 𝑀𝑊𝐴𝑏 . 1𝑒
−3 +  𝐴𝑙𝑖𝑣111𝑓𝑟𝑒𝑒. 𝑆𝑖𝑛𝑑𝑖𝑢𝑚. 𝑀𝑊111. 1𝑒
−3  
𝐴𝑐𝑡𝑝𝑙111 = (𝐶𝐴𝑏111. 𝑆𝐴𝑏111. 𝑀𝑊𝐴𝑏 +  𝐶111. 𝑆𝑖𝑛𝑑𝑖𝑢𝑚. 𝑀𝑊111).1𝑒
−6. 𝑃𝑊 
𝐴𝑐𝑡𝑙𝑖𝑣125 = 𝐴𝑙𝑖𝑣125. 𝑆𝐴𝑏125. 𝑀𝑊𝐴𝑏 . 1𝑒
−3 +  (𝐴𝑙𝑖𝑣125𝑓𝑟𝑒𝑒 +
𝐴𝑙𝑖𝑣125𝑓𝑟𝑒𝑒𝑖𝑛). 𝑆𝑖𝑜𝑑𝑖𝑛𝑒. 𝑀𝑊125. 1𝑒
−3   
𝐴𝑐𝑡𝑝𝑙125 = (𝐶𝐴𝑏125. 𝑆𝐴𝑏125. 𝑀𝑊𝐴𝑏 +  𝐶125. 𝑆𝑖𝑜𝑑𝑖𝑛𝑒. 𝑀𝑊125).1𝑒
−6. 𝑃𝑊 
Supplementary table 10: Variables and parameters involved in the model 
Variable/ 
Parameter 
Description Unit 
𝐶𝑐 non-radiolabeled antibodies concentration in plasma nM 
𝐶𝑝 non-radiolabeled antibodies concentration in tissue nM 
𝐶𝐴𝑏111 111In Ab concentration in plasma nM 
𝐶𝑝𝐴𝑏111 111In Ab concentration in tissue nM 
𝐶𝐴𝑏125 125I Ab concentration in plasma nM 
𝐶𝑝𝐴𝑏125 125I Ab concentration in tissue  nM 
𝐶111 plasma free 111In concentration nM 
𝐶125 plasma free 125I concentration nM 
𝐶𝑝125 tissue free 125I concentration   nM 
𝑅 ASGPR concentration nM 
𝑅𝐿 ASGPR-non-radiolabeled Ab complex concentration at the cell 
surface of the hepatocytes 
nM 
𝑅𝐿𝐴𝑏111 ASGPR-111In Ab complex concentration at the cell surface of the 
hepatocytes 
nM 
𝑅𝐿𝐴𝑏125 ASGPR-125I Ab complex concentration at the cell surface of the 
hepatocytes 
nM 
𝑅𝐿𝑖𝑛111 ASGPR-111In Ab antibody complex concentration internalized in 
the hepatocytes 
nM 
𝐼𝑛𝑑𝑖𝑢𝑚𝑖𝑛 free 111In residualizing inside the hepatocytes after that the 111In 
Ab are degraded 
nM 
𝐴𝑙𝑖𝑣111 111In Ab amount measured in the liver nmol 
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𝐴𝑙𝑖𝑣111𝑓𝑟𝑒𝑒 free 111In amount measured in the residual plasma of the liver nmol 
𝐴𝑙𝑖𝑣125 125I Ab amount measured in the liver nmol 
𝐴𝑙𝑖𝑣125𝑓𝑟𝑒𝑒 free 125I amount measured in the residual plasma of the liver nmol 
𝐴𝑙𝑖𝑣125𝑓𝑟𝑒𝑒𝑖𝑛  free 125I amount measured in the liver nmol 
𝑆𝐴𝑏111 Specific activity of 111In Ab at the time of observation µCi/g 
𝑆𝐴111 Specific activity of 111In Ab at the time of injection µCi/g 
𝑆𝐴𝑏125 Specific activity of 125I Ab at the time of observation µCi/g 
𝑆𝐴125 Specific activity of 125I Ab at the time of injection µCi/g 
𝑆𝑖𝑛𝑑𝑖𝑢𝑚 Specific activity of 111In at the time of observation µCi/g 
𝑆111 Specific activity of 111In at the time of injection µCi/g 
𝑆𝑖𝑜𝑑𝑖𝑛𝑒 Specific activity of 1125I at the time of observation µCi/g 
𝑆125 Specific activity of 125I at the time of injection µCi/g 
𝛾111 Radioactivity decay of 111In hour-1 
𝛾125 Radioactivity decay of 125I hour-1 
𝐴𝑐𝑡𝑙𝑖𝑣111 111In radioactivity in liver µCi 
𝐴𝑐𝑡𝑙𝑖𝑣125 125I radioactivity in liver µCi 
𝐴𝑐𝑡𝑝𝑙111 111In radioactivity in plasma µCi 
𝐴𝑐𝑡𝑝𝑙125 125I radioactivity in plasma µCi 
𝑀𝑊111 Molecular weight of 111In g/mol 
𝑀𝑊125 Molecular weight of 125I g/mol 
𝑀𝑊𝐴𝑏 Molecular weight of the antibody g/mol 
𝑃𝑊 Plasma weight of the sample mL 
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Discussion and future perspectives 
 
Two pharmacokinetic studies were conducted to quantify the ASGPR mediated uptake key 
parameters in vivo to guide the optimization of protocol of administration for ASGPR targeted 
drugs. We used a human IgG1 antibody that specifically binds with high affinity to the ASGPR 
as a tool to infer the properties of the receptor from the plasma concentrations over time. We 
chose to use an antibody because of two reasons 1) the antibody was designed to bind 
specifically to the ASGPR 2) the clearance of antibodies are usually much slower than the 
target-mediated processes making a time dissociation between the ASGPR mediated processes 
and non-target related PK processes possible and visible in the pharmacokinetic data.  
The main uptake properties of the ASGPR uptake were estimated from a mouse PK study, 
such as the receptor expression, the receptor turnover and the receptor-ligand complex 
internalization half-lives. The ASGPR concentration in liver was estimated to be 0.647 µM 
which is similar to what has been estimated in human (0.736-0.792 µM) [57, 68]. This 
concentration can be converted in number of receptors resulting in about 1.8 million receptors 
at the cell surface of the hepatocytes, also similar to the human receptor total capacity of 
approximately 1 million per hepatocyte [42]. While the receptor expression is a key parameter 
to predict the uptake of a targeting drug in the hepatocyte, alone it is not sufficient. The PK 
analysis allowed the estimation of turnover dynamics for the receptors at the cell surface. The 
half-life of the degradation of the receptor was found to be about 15 hours and the synthesis 
rate, a zero-order rate, was estimated to be about 30 nM/hour (i.e. 5% of the total receptor pool 
is produced every hour). This synthesis rate represents different contributing processes such as 
protein synthesis, internalization and recycling of internalized receptors back to the cell surface 
and mobilization of intracellular receptors. The antibody-ASGPR complex is internalized with 
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a half-life of approximately 5 days. An illustration of the ASGPR mediated endocytosis 
parameters are represented in the Figure 11, which are necessary for the prediction of the 
hepatocyte uptake of any ASGPR targeting drug. 
 
Figure 11: Schematic representation of the uptake kinetic model at the hepatocyte level. The 
antibody - or a targeting drug – binds to the receptor with a certain affinity which is dependent 
on the ASGPR but also on the targeting drug. For the antibody used in the two PK studies we 
found a dissociation constant of 4.1 nM.  Other processes are independent of the targeting drug 
as the synthesis and the degradation rate of the receptor and the internalization rate.  
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We performed a biodistribution study to confirm the inferred and specific liver uptake 
from the first PK study. Motivated by precedent exploratory PK studies involving dual 
antibody labeling [237, 238], significant methodological efforts were made to generate a stable 
dual radiolabeled ASGPR Ab and design the biodistribution study. These efforts resulted in the 
measure of the liver uptake of the ASGPR Ab and its distribution in other tissues. A large 
distribution of the ASGPR Ab was detected in liver and minor distribution was noted in other 
tissues, confirming the rapid and extensive binding of the ASGPR Ab in the liver. In order to 
differentiate the specific uptake of the ASGPR Ab from the general liver clearance of 
antibodies, a radiolabeled non-targeting antibody (IL17 Ab) was used as a control. In 
comparison to the ASGPR Ab, the IL17 Ab poorly distributes in liver confirming the specific 
distribution of the ASGPR Ab into the liver.  In case of non-saturating dose (1 mg/kg), almost 
the totality of the dose (87%) was found to bind to the liver 5 minutes after IV administration. 
Therefore, it was concluded that the ASGPR-mediated uptake of the antibody happens solely 
in the liver and therefore it confirms the quantitative description of the ASGPR mediated 
uptake. 
The two in-vivo studies allowed a quantitative description of the ASGPR mediated 
endocytosis through a mathematical model which describes the PK of an ASGPR targeting Ab 
in the plasma and its liver uptake. The liver uptake is dependent on both the PK of the targeting 
drug and on the ASGPR mediated endocytosis. This ASGPR mediated disposition model was 
then used to investigate the influence of the protocol of administration on the delivery outcome 
and discussed how to optimize ASGPR targeting delivery. Two optimization criteria are 
proposed 1) the quantity of the drug delivered in the liver (targeting intensity) and 2) the 
percentage of the drug delivered to the liver (delivery efficiency), see Table 5. Combining those 
two criteria, we demonstrate that both the non-target related PK parameters and the binding 
properties influence the liver uptake. Both criteria together with the ASGPR mediated drug 
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disposition model inform on what non-ASGPR related PK parameters or binding properties 
need to be considered for a tailored drug dosage regimen. 
Table 5: ASGPR targeting optimization criteria 
Criteria Targeting intensity Delivery efficiency 
Definition Quantity of the drug delivered in the 
liver 
Percentage of the drug delivered to 
the liver 
Utility Link the PK and the PD of the 
ASGPR targeting drug: the criteria 
is an indicator of concentration in 
the targeted tissue that can be 
compared to an efficacy threshold 
(e.g. concentration for half-
maximal effect, 𝐸𝐶50) 
Mitigate off-target toxicity: the 
criteria is an indicator of how much 
of the dose is delivered to the liver 
as opposed to be distributed in non-
targeted tissues 
 
We suggest the following use of the ASGPR-mediated disposition model. First, it can 
be applied to any molecular entity targeting the ASGPR to optimize the targeting intensity and 
delivery efficiency criteria taking into account their non-ASGPR related PK properties. 
Second, the ASGPR mediated drug disposition model Extrapolation of the mouse model to 
human is the final goal in order to select an optimal dosing regimen of ASGPR targeting drugs 
in patients. In human, some parameters are already known such as the receptor expression [42, 
43] but other processes of the receptor mediated endocytosis must however be investigated 
such as the synthesis and degradation rate. After validation in human, the model will be 
applicable to estimate the receptor number in patients. This parameter is crucial to adapt their 
dosing regimen since patients with liver disease often show reduced receptor expression. 
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